



(12) **EUROPEAN PATENT APPLICATION**

(43) Date of publication:
02.05.2002 Bulletin 2002/18

(51) Int Cl.⁷: **C12Q 1/48**, C07K 16/00,
A61P 31/12, A61K 39/395,
A61K 48/00, C12Q 1/68

(21) Application number: **01124604.8**

(22) Date of filing: **15.10.2001**

(84) Designated Contracting States:
AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU
MC NL PT SE TR
Designated Extension States:
AL LT LV MK RO SI

• **Stein-Gerlach, Matthias**
81475 Munich (DE)
• **Bevec, Dorian**
82110 Germering (DE)

(30) Priority: **16.10.2000 US 240750 P**

(74) Representative: **Leidescher, Thomas et al**
Zimmermann & Partner,
Postfach 33 09 20
80069 München (DE)

(71) Applicant: **Axxima Pharmaceuticals**
Aktiengesellschaft
82152 Martinsried (DE)

Remarks:

The sequence listing, which is published as annex to the application documents, was filed after the date of filing. The applicant has declared that it does not include matter which goes beyond the content of the application as filed.


(72) Inventors:
• **Schubart, Daniel**
79576 Weil am Rhein (DE)
• **Habenberger, Peter**
81373 Munich (DE)

(54) **Cellular kinases involved in cytomegalovirus infection and their inhibition**

(57) The role of certain cellular kinases active during Human Cytomegalovirus infection is disclosed. These cellular kinases are useful to detect HCMV infection,

and can be used to screen for cellular kinase inhibitors. Cellular kinases inhibitors, which effectively downregulate these key cellular components, serve as effective therapeutics against HCMV infection.

Fig. 1



Description

[0001] The present invention is in the fields of molecular biology and virology. The present invention is directed to novel methods for treating Cytomegalovirus using kinase inhibitors.

Background of the invention

[0002] Human Cytomegalovirus (HCMV) is a highly specific β -herpesvirus. Primary infection of healthy children and adults is usually asymptomatic, with a minority of cases developing a mononucleose-like syndrome. In contrast, congenital infection (U.S. 0.2%-2.2% per live birth; approx. 40,000 per year) leads to several neurological defects in 10-15% of infected neonates. Immunocompromised patients represent another host group facing serious disease complications caused by HCMV infection or reactivation of a persistent infection. Up to 40% of the AIDS patients, for example, develop retinitis, pneumonitis, gastroenteritis or disseminated HCMV disease. In addition, allograft recipients (20,000 allograft transplantations per year in the U.S.) are often infected (or superinfected) by virus from the transplanted organ.

[0003] Clinical symptoms in the posttransplant period include prolonged fever, leukopenia, thrombocytopenia, atypical lymphocytosis, elevated hepatic transaminases and decreased graft survival. In bone marrow transplantations, HCMV infection is associated with high mortality rates (80-90% for untreated HCMV pneumonia).

[0004] Current approaches to develop therapeutics against Cytomegalovirus (CMV) have focused on antiviral agents *per se*; for example viral polymerase inhibitors. In fact, high mortality rates have been dramatically reduced by new antiviral agents. Current CMV therapeutics possess severe drawbacks, however. For example, Fomivirsen (Vitravene, formerly ISIS 2922) is typically administered by injection directly into the eye every 2 or 4 weeks. Ganciclovir is available for intravenous (Cytovene) or oral administration, and as an implant in the case of retinitis; unfortunately, toxic complications including leukopenia and thrombocytopenia frequently develop. Foscarnet (Foscavir; phosphonoformic acid), another antiviral agent, exhibits considerable renal toxicities and is only available in intravenous form (which is also true for Cidofovir (Vistide), another CMV therapeutic). In addition, CMV replication resumes soon after Ganciclovir and Foscarnet treatment is halted. Finally, Ganciclovir- and Foscarnet-resistant strains of CMV are emerging.

[0005] Although treatment of HCMV-induced disease has been improved with these inhibitors of the viral polymerase and preemptive or early antiviral therapy in transplant patients, there is a need in the art for a new class of HCMV therapeutics with better oral bioavailability and reduced toxic effects. This is especially true in the treatment of retinitis in AIDS patients, where CMV infection must be controlled for long periods of time.

[0006] Recent research has revealed how cells communicate with each other to coordinate the growth and maintenance of the multitude of tissues within the human body. A key element of this communication network is the transmission of a signal from the exterior of a cell to its nucleus, which results in the activation or suppression of specific genes. This process is called signal transduction.

[0007] An integral part of signal transduction is the interaction of cytokines, their receptors, and intracellular signal transduction molecules. Cytokines serve as messengers that bind to receptors on the surface of a target cell. As a result of the binding, the receptors activate a cascade of downstream signaling molecules, thereby transmitting the message from the exterior of the cell to its nucleus. Signal transduction to the nucleus modulates specific gene expression (i.e., transcription and translation), which results in either the upregulation or downregulation of specific proteins that carry out a particular biological function.

[0008] Viral infection disrupts normal signal transduction, which leads to cellular malfunctioning resulting in a disease state. Specifically, interference of HCMV with relevant human primary cells is necessary for the virus to create an environment that allows it to grow and replicate, and in turn cause disease in the infected individual. Current research efforts have failed to elucidate all the specific intracellular signal pathways affected by HCMV infection, however. Discovery of the signal transduction pathways and specific intracellular signal transduction molecules affected by CMV infection would represent a tremendous advance in the understanding of the induction and progression of CMV infection processes and provide new avenues for the development of a novel class of effective therapeutics for the treatment of CMV.

[0009] Thus, object of the present invention is to provide methods for detecting, preventing and/or treating Cytomegalovirus infection and/or associated diseases, methods for the identification of compounds useful for preventing and/or treating Cytomegalovirus infection and/or associated diseases and for regulating the production of Cytomegaloviruses.

[0010] The object of the present invention is solved by the teaching of the independent claims. Further advantageous features, aspects and details of the invention are evident from the dependent claims, the description, and the examples of the present application.

Description of the invention

[0011] The present invention is based upon the finding of a group of cellular kinases that are specifically upregulated as a result of CMV infection. The antiviral therapeutic research approach described herein, focuses on discovering the cellular signal transduction pathways involved in viral infection. Identification of the cellular signal transduction molecules, key to viral infection provides for, among other things, novel diagnostic methods, especially assays, and compositions useful therefor, novel targets for antiviral therapeutics, a novel class of antiviral therapeutics, and new screening assays and materials to discover new antiviral agents.

[0012] This approach led to the development of a novel microarray platform technology, wherein a microarray of more than 1100 signal transduction cDNAs was developed. This unique microarray technology was used to identify RNA expression patterns (e.g., upregulation or downregulation) unique to CMV infected host cells. Differential display techniques were used to pinpoint those signal transduction molecules useful as targets for drug intervention. Effective manipulation of these virally-controlled intracellular signal transduction pathways can alter (slow or stop altogether) the course of viral growth.

[0013] It is now revealed for the first time that the cellular protein kinases RICK (also known as CARDIAK; RIP2), RIP, NIK (also known as HGK; MAP4K4), MKK3 (also known as MEK3), and SRPK-2 are specifically and uniquely upregulated in a cell as a result of CMV infection. These cellular kinases therefore identify novel diagnostic and therapeutic targets for CMV infection.

[0014] Surprisingly, it was found that the following human cellular targets are significantly upregulated compared with uninfected human foreskin fibroblasts cells:

target	upregulation
RICK	3.6 fold
RIP	2.6 fold
NIK	4.0 fold
MKK3	2.5 fold
SRPK-2	2.2 fold

[0015] Based upon the research work reported herein, one aspect of the present invention is directed to a method, preferably a screening assay, for identifying compounds useful for treating and/or preventing Cytomegalovirus infection and/or diseases associated therewith. Specifically, this assay involves contacting a test compound with one or more cellular kinases selected from the group consisting of RICK, RIP, NIK, MKK3, and SRPK-2, and detecting a change, normally a decrease, in activity of said cellular kinase. This method was used for the identification of the RICK and RIP inhibitors shown below in Table 1 and Table 2.

[0016] Another aspect of the invention is directed to a diagnostic method for detecting Cytomegalovirus infection and/or associated diseases in an individual or in cells and/or in cell lysates. This assay involves providing a sample from the individual or providing a sample from said cells, respectively, and detecting activity of one or more cellular kinases selected from the group consisting of RICK, RIP, NIK, MKK3, and SRPK-2. The term "individual" preferably refers to mammals, especially humans or ruminants.

[0017] Also described in the present invention are monoclonal or polyclonal antibodies which bind to a cellular kinase selected from the group consisting of RICK, RIP, NIK, MKK3, and SRPK-2.

[0018] A further aspect of the present invention relates to a method for preventing and/or treating Cytomegalovirus infection and/or associated diseases in an individual by administering a pharmaceutically effective amount of an inhibitor to said individual, wherein said inhibitor inhibits at least partially the activity of one or more cellular kinases selected from the group consisting of RICK, RIP, NIK, MKK3, and SRPK-2, or wherein said inhibitor inhibits at least partially the production of one or more cellular kinases selected from the group consisting of RICK, RIP, NIK, MKK3, and SRPK-2.

[0019] As used herein, the term "inhibitor" refers to any compound capable of downregulating, decreasing, reducing, suppressing or inactivating the amount and/or activity of at least one human cellular protein kinase selected from the group consisting of RICK, RIP, NIK, MKK3, and SRPK-2. Generally, said inhibitors, including suicide inhibitors, may be proteins, oligo- and polypeptides, nucleic acids, genes, small chemical molecules, or other chemical moieties. Suitable inhibitors are monoclonal or polyclonal antibodies which bind to at least one cellular kinase selected from the group consisting of RICK, RIP, NIK, MKK3, and SRPK-2.

[0020] Based on the surprising results reported herein, one aspect of the present invention is directed to a method for regulating the production of Cytomegalovirus in an individual by administering an individual a pharmaceutically effective amount of an inhibitor wherein said inhibitor inhibits at least partially the activity of one or more cellular kinases selected from the group consisting of RICK, RIP, NIK, MKK3, and SRPK-2, or wherein said inhibitor at least partially

inhibits the production of one or more cellular kinases selected from the group consisting of RICK, RIP, NIK, MKK3, and SRPK-2.

[0021] A similar aspect relates to a method for regulating the production of Cytomegalovirus in cells by administering the cells a pharmaceutically effective amount of an inhibitor wherein said inhibitor inhibits at least partially the activity of one or more cellular kinases selected from the group consisting of RICK, RIP, NIK, MKK3, and SRPK-2, or wherein said inhibitor at least partially inhibits the production of one or more cellular kinases selected from the group consisting of RICK, RIP, NIK, MKK3, and SRPK-2 in the cells.

[0022] Yet another aspect of the invention is directed to a method for regulating the expression of at least one cellular kinase selected from the group consisting of RICK, RIP, NIK, MKK3, and SRPK-2 in an individual comprising the step of administering the individual a pharmaceutically effective amount of an inhibitor wherein said inhibitor inhibits at least partially the transcription of DNA or the translation of RNA encoding one of said cellular kinases.

[0023] A further aspect relates to a method for regulating the expression of at least one cellular kinase selected from the group consisting of RICK, RIP, NIK, MKK3, and SRPK-2 in the cells comprising the step of administering the cells a pharmaceutically effective amount of an inhibitor wherein said inhibitor inhibits at least partially the transcription of DNA or the translation of RNA encoding one of said cellular kinases.

[0024] As used herein, the term "regulating expression and/or activity" generally refers to any process that functions to control or modulate the quantity or activity (functionality) of a cellular component. Static regulation maintains expression and/or activity at some given level. Upregulation refers to a relative increase in expression and/or activity. Accordingly downregulation refers to a relative decrease in expression and/or activity. In the present invention, regulation is preferably the downregulation of a cellular component. Downregulation is synonymous with inhibition of a given cellular component's activity.

[0025] Beside inhibitors also activators may be useful for treating Cytomegalovirus infection by increasing the activity of at least one of the cellular protein kinases RICK, RIP, NIK, MKK3, and SRPK-2. Thus, a method for preventing and/or treating Cytomegalovirus infection and/or associated diseases in an individual is disclosed. Said method comprises administering a pharmaceutically effective amount of an activator to an individual, wherein said activator activates at least partially the activity of one or more cellular kinases selected from the group consisting of RICK, RIP, NIK, MKK3, and SRPK-2, or wherein said activator activates or stimulates at least partially the production of one or more cellular kinases selected from the group consisting of RICK, RIP, NIK, MKK3, and SRPK-2.

[0026] Furthermore, a method for regulating the production of Cytomegalovirus either in cells or in an individual is described. Said methods comprise administering an individual or to cells a pharmaceutically effective amount of an activator wherein said activator activates at least partially the activity of one or more cellular kinases selected from the group consisting of RICK, RIP, NIK, MKK3, and SRPK-2, or wherein said activator at least partially activates or stimulates the production of one or more cellular kinases selected from the group consisting of RICK, RIP, NIK, MKK3, and SRPK-2.

[0027] As used herein, the term "activator" refers to any chemical compound which is able to upregulate, increase, activate, or stimulate the activity of at least one human cellular protein kinase selected from the group consisting of RICK, RIP, NIK, MKK3, and SRPK-2 or which is able to upregulate, increase, activate, or stimulate the expression of at least one of said cellular kinases. Activators comprise proteins, oligo- and polypeptides, nucleic acids, genes, and preferably small chemical molecules, or other chemical moieties.

[0028] Still another aspect of the present invention is directed to either a method for regulating the expression of at least one cellular kinase selected from the group consisting of RICK, RIP, NIK, MKK3, and SRPK-2 in an individual or for regulating the expression of at least one of said kinases in cells. These methods comprise the step of administering the individual or the cells a pharmaceutically effective amount of an activator wherein said activator activates at least partially the transcription of DNA or the translation of RNA encoding one of said cellular kinases.

[0029] Furthermore, oligonucleotides are disclosed which bind to the DNA or RNA encoding a cellular kinase selected from the group consisting of RICK, RIP, NIK, MKK3, and SRPK-2. Said oligonucleotides can be used as suitable inhibitors within the aforementioned methods.

[0030] Some methods of the present invention identify compounds useful for prophylaxis and/or treatment of Cytomegalovirus infection and/or associated disease by screening a test compound, or a library of test compounds, for its ability to inhibit at least one of the above-mentioned human cellular protein kinases identified herein as characteristically upregulated during HCMV replication. Using this method the compounds A to E have been identified as RICK inhibitors and the compounds F to H have been identified as RIP inhibitors. Thus, the use of these compounds as inhibitors of RICK or RIP is disclosed. Furthermore, these compounds can be used for manufacturing a pharmaceutical composition for prophylaxis and/or treatment of Cytomegalovirus infection and/or diseases associated with Cytomegalovirus infection.

[0031] A variety of assay protocols and detection techniques are well known in the art and easily adapted for this purpose by a skilled practitioner. Such methods include, but are not limited to, high throughput assays (e.g., microarray technology, phage display technology), and *in vitro* and *in vivo* cellular and tissue assays.

[0032] Thus, some embodiments of the present invention may comprise a solid support useful for detecting Cytomegalovirus infection in a cell or an individual. Preferably the solid support comprises immobilized oligonucleotides, wherein the oligonucleotides are capable of detecting activity of one or more cellular kinases selected from the group consisting of: RICK, RIP, NIK, MKK3, and SRPK-2.

[0033] Another aspect of the invention includes a solid support useful for screening compounds useful for treating Cytomegalovirus. Preferred embodiments include a solid support comprising one or more immobilized oligonucleotides, wherein the oligonucleotide(s) encode one or more cellular kinases selected from the group consisting of RICK, RIP, NIK, MKK3, and SRPK-2. In another preferred embodiment, the solid support comprises one or more immobilized cellular kinases selected from the group consisting of: RICK, RIP, NIK, MKK3, and SRPK-2.

[0034] Accordingly, another aspect of the present invention is directed to a novel therapeutic composition useful to treat an individual afflicted with Cytomegalovirus comprising one or more inhibitors capable of inhibiting activity of one or more of the cellular kinases selected from the group consisting of RICK, RIP, NIK, MKK3, and SRPK-2. In addition thereto, a novel pharmaceutical composition could comprise at least one inhibitor capable of regulating the production of HCMV by inhibiting the expression of at least one cellular kinase selected from the group consisting of RICK, RIP, NIK, MKK3, and SRPK-2.

[0035] Another group of suitable therapeutic compositions useful for prophylaxis and/or treatment of CMV comprises at least one activator which is able to increase the activity of one or more cellular kinases selected from the group consisting of RICK, RIP, NIK, MKK3, and SRPK-2 or which is capable of increasing the expression of at least one cellular kinase selected from the group consisting of RICK, RIP, NIK, MKK3, and SRPK-2.

[0036] Said pharmaceutical compositions may further comprise pharmaceutically acceptable carriers, excipient, diluents, fillers, binders, disintegrants, lubricants, glidants, coloring agents, flavoring agents, opaquing agents, and/or plasticizers.




Detailed description of the invention



[0037] Utilizing microarray technology, a unique microarray of more than 1100 signal transduction cDNAs was developed. This array was used to compare signal transduction mRNA expression patterns (e.g., upregulation or down-regulation) in primary human cells before and after infection with HCMV at various timepoints of infection. Interference of the HCMV with the cellular signaling events is reflected in differential gene expression when compared to the uninfected cellular signaling. Results from this novel signal transduction microarray analysis revealed significant upregulation of cellular protein kinases RICK, RIP, NIK, MKK3, and SRPK-2, as unique to CMV infected host cells. These findings were confirmed utilizing conventional Northern and Western blot analyses.

[0038] Disclosed herein is the first report describing the role of cellular kinases; RICK, RIP, NIK, MKK3, and SRPK-2 in the signal transduction of CMV viral infection process. As a result of these discoveries, a novel class of compounds, i.e., RICK, RIP, NIK, MKK3, and SRPK-2 inhibitors, are identified as useful for altering the course of CMV infection.

[0039] To perform initial tests for compounds that inhibit RICK activity in a cellular assay, RICK was transiently over-expressed in HEK-293 cells, immunoprecipitated and incubated with different concentrations of test compounds before in-vitro kinase assays were performed (Example 10). According to the method for identifying compounds useful for inhibiting the cellular kinase RICK and therefore useful for treating and/or preventing Cytomegalovirus infection and/or diseases associated with Cytomegalovirus infection, a test compound is contacted with the cellular kinase RICK according to the RICK assay protocol disclosed in example 10. The test compound dissolved in DMSO is added to the RICK assay solution at concentrations between 100 nM and 50 μ M. Thereafter, radioactively labeled ATP is added and kinase activity of RICK is determined by detecting the autophosphorylation of RICK via radioactivity measurement. The five compounds listed in the following Table 1 were identified using said method. These compounds showed inhibition of RICK kinase activity with an IC_{50} between about 500 nM and 1 μ M and an inhibition of HCMV with an IC_{50} between about 1 and 8 μ M, respectively. The IC_{50} values of HCMV inhibition were obtained by the use of at least one assay protocol selected from a) virus replication assay, b) plaque assay, c) GFP (Green Fluorescent Protein) infection assay, and d) indirect immunofluorescence analysis as disclosed in example 12. Thus, the five compounds A to E mentioned below and/or pharmaceutically acceptable salts thereof can be used as inhibitors of the cellular protein kinase RICK and as pharmaceutically active compounds for the treatment and/or prophylaxis of HCMV infection. Furthermore, these compounds are suitable for the manufacture of a pharmaceutical composition for prophylaxis and/or treatment of Cytomegalovirus infection and/or diseases associated therewith.

Table 1: Inhibitors of RICK and HCMV

compound	structure	IC ₅₀ RICK	IC ₅₀ HCMV
A		1 μ M	6.8 μ M
B		500 nM	1.4 μ M
		1 μ M	6.2 μ M

<div style="position: absolute; left: 5px; top: 5px;">5</div> <div style="position: absolute; left: 5px; top: 15px;">10</div>		500 nM	7.6 μ M
<div style="position: absolute; left: 5px; top: 15px;">15</div> <div style="position: absolute; left: 5px; top: 25px;">20</div>	<div style="position: absolute; left: 10px; top: 10px;">E</div> 	500 nM	5.7 μ M

[0040] The compounds A to E have the following names:

Compound A: 6-(2,6-Dichlorophenyl)-8-methyl-2-(3-morpholin-4-yl-propylamino)-8*H*-pyrido[2,3-*d*]pyrimidin-7-one;

Compound B: 8-methyl-6-phenyl-2-(pyridin-4-yl-amino)-8*H*-pyrido[2,3-*d*]pyrimidin-7-one;

Compound C: 6-(2,6-Dichlorophenyl)-8-methyl-2-[3-(4-methylpiperazin-1-yl)-propylamino]-8*H*-pyrido[2,3-*d*]pyrimidin-7-one;

Compound D: (3-Bromophenyl)-(6,7-diethoxyquinazolin-4-yl)-amine;

Compound E: (3-Bromophenyl)-(6,7-dimethoxyquinazolin-4-yl)-amine.




[0041] From the results observed with the compounds shown in Table 1 it is proved that RICK is an important target for the treatment of HCMV and diseases associated with HCMV infection. Inhibitors of the human cellular protein kinase RICK may serve as new pharmaceutical substances for prophylaxis and/or treatment of Cytomegalovirus infection and/or diseases associated with CMV infection.

[0042] In addition to the chemical validation of RICK described above, a genetic validation of RICK in HCMV infection was performed. Wildtype and mutated RICK was expressed in HFF cells with a modified Adenovirus as vehicle (Example 9). The expression of both, wildtype and mutated RICK, caused a dramatic reduction in HCMV replication (cf. Fig. 2). Also these data confirm RICK as a valuable therapeutic target in HCMV treatment. As known in the art and as used herein, "RICK" refers to a protein kinase also known as "CARDIAK" and as "RIP2" which is a RIP-like kinase. RICK is essentially characterized as comprising an N-terminal serine-threonine kinase catalytic domain and a C-terminal region containing a caspase-recruitment domain (referred to as "CARD").

[0043] To perform initial tests for compounds that inhibit RIP activity in a cellular assay, RIP was transiently overexpressed in HEK-293 cells, immunoprecipitated and incubated with different concentrations of test compounds before in-vitro kinase assays were performed (Example 11). In order to identify compounds suitable for inhibiting the cellular kinase RIP and, thus, suitable for treating and/or preventing Cytomegalovirus infection and/or diseases associated with Cytomegalovirus infection the inventive method according to claim 1 was used. A test compound was contacted with the cellular kinase RIP according to the RIP assay protocol disclosed in example 11. The test compound dissolved in DMSO is added to the RIP assay solution at concentrations between 100 nM and 50 μ M. Radioactively labeled ATP was used as co-substrate of RIP and auto-phosphorylation was detected via measurement of incorporation of radioactivity into the RIP protein. Thereafter, phosphorylation rates with and without test compounds were compared. The three compounds listed in the following Table 2 showed inhibition of RIP kinase activity with an IC_{50} between about 5 μ M and 10 μ M and an inhibition of HCMV with an IC_{50} between about 12 μ M and 15 μ M, respectively. The IC_{50} values of HCMV inhibition were obtained by the use of at least one assay protocol selected from a) virus replication assay, b) plaque assay, c) GFP infection assay, and d) indirect immunofluorescence analysis as disclosed in example 12.

[0044] Thus, the three compounds F to H mentioned below and/or pharmaceutically acceptable salts thereof can be used as inhibitors of the cellular protein kinase RIP and as pharmaceutically active compounds for the treatment and/or prophylaxis of HCMV infection. Furthermore, these compounds are suitable for the manufacture of a pharmaceutical composition for prophylaxis and/or treatment of Cytomegalovirus infection and/or diseases associated therewith.

Table 2: Inhibitors of RIP and HCMV

compound	structure	IC ₅₀ RIP	IC ₅₀ HCMV
		5 μ M	15 μ M
		10 μ M	15 μ M
H		5 μ M	12 μ M

[0045] The compounds F to H have the following names:

Compound F: 2-(3,4-Dihydroxyphenyl)-3,5,7-trihydroxychromen-4-one;

Compound G: 5-Chloro-3-(1*H*-pyrrol-2-ylmethylene)-1,3-dihydroindol-2-one;

Compound H: 4-Quinolin-4-ylmethylene-4*H*-isoquinoline-1,3-dione.

[0046] From the results observed with the compounds shown in Table 2 it is proved that RIP is an important target for the treatment of HCMV and diseases associated with HCMV infection. Inhibitors of the human cellular protein kinase RIP may serve as new pharmaceutical substances for prophylaxis and/or treatment of Cytomegalovirus infection and/or diseases associated with CMV infection.

[0047] In addition to the chemical validation of RIP described above, a genetic validation of RIP in HCMV infection was performed. Wildtype and mutated RIP was expressed in HFF cells with a modified Adenovirus as vehicle (Example 9). The expression of mutated RICK, but not wildtype RIP, caused a dramatic reduction in HCMV replication (cf. Fig. 1). These data also confirm RIP as therapeutic target in HCMV treatment.

[0048] As known in the art and as used herein, "NIK" (Nck-Interacting Kinase; also known as "HGK" or "MAP4K4") refers to an NF-kappaB inducing serine/threonine kinase that interacts with the SH3 domains of Nck (an adaptor protein composed of one SH2 and three SH3 domains, known as a common target for a variety of cell surface receptors). NIK is most homologous to the Sterile 20 (Ste20) family of protein kinases, particularly GCK and MSST1 in that they bind

neither Cdc42 nor Rac and contain an N-terminal kinase domain with a putative C-terminal regulatory domain. NIK is reported to promote neurite process formation and mediated anti-apoptotic signaling. NIK expression leads to IKK activation and induced nuclear translocation of NF-kappaB. NIK activates MEK1 phosphorylation and induces the Erk1/Erk2 MAPK pathway. NIK has been shown to be a MEK1-dependent activator of the MAPK pathway (Foehr et al., 2000. *J. Biol. Chem.* 275, 34021-34024). Overexpression of NIK has been reported to specifically activate the stress-activated protein kinase (SAPK) pathway; possibly upstream of MEKK1, a dominant-negative MEK kinase 1 capable of blocking NIK activation of SAPK (Su et al., 1997. *EMBO* 16(6):1279-90).

[0049] As known in the art and as used herein, "MKK3" (MAP kinase kinase 3; also known as "MEK3") refers to a protein kinase known to function in TNF-induced cytokine expression, and specifically phosphorylate and activate p38 MAP kinase (Blank et al., 1996. *J. Biol. Chem.* 271:5361-5368; Raingeaud et al., 1996. *Mol. Cell. Biol.* 16(3):1247-55). MKK3 gene disruption has been shown to cause a selective defect in the response of fibroblasts to the proinflammatory cytokine tumor necrosis factor, including reduced p38 MAP kinase activation and cytokine expression; suggesting that the MKK3 protein kinase is a critical component of a tumor necrosis factor-stimulated signaling pathway that causes increased expression of inflammatory cytokines (Wysk et al., 1999. *PNAS USA* 96(7):3763-8).

[0050] As known in the art and as used herein, "SRPK-2" (SR-protein-specific kinase 2) refers to a kinase known to phosphorylate SF2/ASF and believed to regulate the disassembly of the SR family of splicing factors in a tissue-specific manner (e.g., in testis, lung, and brain; Kuroyanagi et al., 1998. *Biochem. Biophys. Res. Commun.* 242(2):357-64). SRPK-2 is believed to function in spliceosome assembly and in mediating the trafficking of splicing factors (Wang et al., 1998. *J. Cell. Biol.* 140(4):737-50; Wang et al., 1999. *Genomics* 57(2):310-5).

[0051] In one embodiment, the present invention is directed to a method for treating CMV infection by administering a pharmaceutically effective amount of an inhibitor of one or more of the cellular kinases; RICK, RIP, NIK, MKK3, and/or SRPK-2.

[0052] As used herein, a cellular kinase "inhibitor" refers to any compound capable of downregulating, decreasing, suppressing or otherwise regulating the amount and/or activity of a cellular kinase. Inhibition of these cellular kinases can be achieved by any of a variety of mechanisms known in the art, including, but not limited to binding directly to the cellular kinase polypeptide (e.g., a RICK-inhibitor compound binding complex, or substrate mimetic), denaturing or otherwise inactivating the cellular kinase, or inhibiting the expression of the gene (e.g., transcription to mRNA, translation to a nascent polypeptide, and/or final polypeptide modifications to a mature protein), which encodes the cellular kinase. Generally, cellular kinase inhibitors may be proteins, polypeptides, nucleic acids, small molecules, or other chemical moieties.

[0053] Yet another aspect of the present invention is directed to pharmaceutical compositions useful for the prophylaxis and/or treatment of an individual afflicted with Cytomegalovirus infection and/or associated diseases. Said pharmaceutical composition comprises at least one pharmaceutically active compound capable of regulating at least partially the activity or the expression of one human cellular protein kinase selected from the group comprising RICK, RIP, NIK, MKK3, and SRPK-2 and/or capable of regulating the replication of CMV.

[0054] As used herein the term "regulating" refers either to the ability of an inhibitor to downregulate, decrease, reduce, suppress, inactivate, or inhibit at least partially the activity of an enzyme, or the expression of an enzyme and the virus replication or to the ability of an activator to upregulate, increase, stimulate, or activate at least partially the activity of an enzyme or the expression of an enzyme.

[0055] Suitable examples for inhibitors which are the pharmaceutically active components within the therapeutic compositions are the compounds A to H mentioned in Table 1 and 2. The compounds 6-(2,6-Dichlorophenyl)-8-methyl-2-(3-morpholin-4-yl-propylamino)-8H-pyrido[2,3-d]pyrimidin-7-one; 8-methyl-6-phenyl-2-(pyridin-4-yl-amino)-8H-pyrido[2,3-d]pyrimidin-7-one; 6-(2,6-Dichlorophenyl)-8-methyl-2-[3-(4-methylpiperazin-1-yl)-propylamino]-8H-pyrido[2,3-d]pyrimidin-7-one; (3-Bromophenyl)-(6,7-dimethoxyquinazolin-4-yl)-amine; (3-Bromophenyl)-(6,7-diethoxyquinazolin-4-yl)-amine; 2-(3,4-Dihydroxyphenyl)-3,5,7-trihydroxychromen-4-one; 5-Chloro-3-(1H-pyrrol-2-ylmethylene)-1,3-dihydroindol-2-one; 4-Quinolin-4-ylmethylene-4H-isoquinoline-1,3-dione and/or pharmaceutically acceptable salts of these compounds are useful for prophylaxis and/or treatment of Cytomegalovirus infection and/or diseases associated with Cytomegalovirus infection.

[0056] CMV therapeutics may be administered to cells from an individual *in vitro*, or may involve *in vivo* administration to the individual. Routes of administration of pharmaceutical preparations to an individual may include inhalation, oral and parenteral, including dermal, intradermal, intragastral, intracutan, intravasal, intravenous, intramuscular, intraperitoneal, intranasal, intravaginal, intrabuccal, percutan, rectal, subcutaneous, sublingual, topical or transdermal application, but are not limited to these ways of administration. For instance, the preferred preparations are in administratable form which is suitable for oral application. These administratable forms, for example, include pills, tablets, film tablets, coated tablets, capsules, powders and deposits. Administration to an individual may be in a single dose or in repeated administrations, and may be in any of a variety of physiologically acceptable salt forms, and/or with an acceptable pharmaceutical carrier, binder, lubricant, excipient, diluents and/or adjuvant. Pharmaceutically acceptable salt forms and standard pharmaceutical formulation techniques are well known to persons skilled in the art (see, for

example, Remington's Pharmaceutical Sciences, Mack Publishing Co.).

[0057] As used herein, a "pharmaceutically effective amount" of a cellular kinase inhibitor is an amount effective to achieve the desired physiological result, either in cells treated *in vitro* or in a subject treated *in vivo*. Specifically, a pharmaceutically effective amount is an amount sufficient to inhibit, for some period of time, one or more of the clinically defined pathological processes associated with the viral infection. The effective amount may vary depending on the specific kinase inhibitor selected, and is also dependent on a variety of factors and conditions related to the subject to be treated and the severity of the infection. For example, if the inhibitor is to be administered *in vivo*, factors such as the age, weight and health of the patient as well as dose response curves and toxicity data obtained in preclinical animal work would be among those considered. If the inhibitor is to be contacted with the cells *in vitro*, one would also design a variety of pre-clinical *in vitro* studies to assess such parameters as uptake, half-life, dose, toxicity, etc. The determination of a pharmaceutically effective amount for a given agent is well within the ability of those skilled in the art.

[0058] As a result of the discovery of the upregulation of certain cellular kinases as part of the infection process of CMV, a novel diagnostic assay useful for the detecting CMV infection of an individual (or cell) is identified. The diagnostic assay of the present invention involves providing a sample from an individual or providing cells and/or cell lysates, and detecting activity in the sample of one or more cellular kinases selected from the group consisting of RICK, RIP, NIK, MKK3, and SRPK-2. In one embodiment, deviations in the expression levels of one or more of the identified cellular kinases in a test sample compared to a known normal expression levels (e.g., determined from a sample from a healthy individual) will be diagnostic of CMV.

[0059] It is apparent to a practitioner in the art that a sample useful for detecting CMV infection, whether of a subject individual or an isolated cell, refers to any cellular extract (including whole cells) from a tissue or body fluid (in the case of an individual) or cellular lysate (in the case of an isolated cell), which contains cellular components representative of cellular activity of one or more of the above-mentioned cellular kinases.

[0060] It is also apparent to a person of ordinary skill in the art that detection includes any method known in the art useful to indicate the presence, absence, or amount of a detection target. Such methods may include, but are not limited to, any molecular or cellular techniques, used singularly or in combination, including, but not limited to: hybridization and/or binding techniques, including blotting techniques and immunoassays; labeling techniques (chemiluminescent, colorimetric, fluorescent, radioisotopic); spectroscopic techniques; separations technology, including precipitations, electrophoresis, chromatography, centrifugation, ultrafiltration, cell sorting; and enzymatic manipulations (e.g., digestion).

[0061] Because the present disclosure teaches for the first time the upregulation of a group of cellular kinases specifically involved in the viral infection of CMV, the present invention is also directed to an assay useful for detecting novel compounds useful for treating CMV infection.

[0062] Assays of the present invention identify compounds useful for treating CMV operate by screening a test compound, or library of test compounds, for its ability to inhibit any one or more of the group of cellular kinases identified herein as characteristically upregulated during CMV growth and replication inside a cell. A variety of assay protocols and detection techniques are well known in the art and easily adapted for this purpose by a skilled practitioner. Such assays include, but are not limited to, high throughput assays (e.g., microarray technology, phage display technology), and *in vitro* and *in vivo* cellular and tissue assays.

[0063] In a related aspect, it is also an object of the present invention, in view of the discovery of cellular kinases specifically involved in CMV growth in a cell, to provide an assay component specially useful for detecting CMV in an individual (or a cell). Preferably the assay component comprises oligonucleotides capable of detecting activity of one or more of the cellular kinases RICK, RIP, NIK, MKK3, and SRPK-2 in a sample (e.g., by hybridization to mRNA from the sample), immobilized on a solid support. Most preferably the solid support would contain oligonucleotides of sufficient quality and quantity to detect all of the above-mentioned cellular kinases (e.g., a nucleic acid microarray).

[0064] Similarly, it is part of the object of the invention to provide an assay component specially useful for screening compounds useful for treating CMV. One preferred assay component comprises oligonucleotides that encode one or more of the cellular kinases RICK, RIP, NIK, MKK3, and SRPK-2, immobilized on a solid support. In another embodiment, the assay component comprises peptide fragments of one or more of the above-identified cellular kinases immobilized on a solid support. Once again the most preferred solid support embodiment would contain polymers of sufficient quality and quantity to detect all of the above-mentioned cellular kinases (e.g., a nucleic acid or a peptide microarray). A variety of assay supports and construction of the same are well known in the art and easily adapted for this purpose by a skilled practitioner (see, for example: Marshall, 1999. "Do-it-yourself gene watching" *Science* 286: 444-447 (including insets); and Service, 2000. "Protein arrays step out of DNA's shadow" *Science* 289:1673).

[0065] It is preferred that mRNA is assayed as an indication of expression. Methods for assaying for mRNA include, but are not limited to, Northern blots, slot blots, dot blots, and hybridization to an ordered array of oligonucleotides. Nucleic acid probes useful for assay of a sample are preferably of sufficient length to specifically hybridize only to appropriate, complementary transcripts. Typically the oligonucleotide probes will be at least 10, 12, 14, 16, 18, 20 or 25 nucleotides in length. In some cases longer probes of at least 30, 40, or 50 nucleotides will be desirable.

[0066] The cDNA oligonucleotides immobilized on said membrane filter which are used for detecting the up- or down-regulation of the above-mentioned human cellular protein kinases by hybridization to the radioactively labeled cDNA probes have the nucleotide sequences listed in table 3.

Table 3:

Nucleotide sequences of cDNA-arrays	
Human cellular kinase	Sequence of immobilized DNA on arrays (in relation to the respective Acc No)
RICK	914 bp - 2501 bp (AF027706)
RIP	1421 bp - 2617 bp (U50062)
NIK	231 bp - 3077 bp (Y10256)
MKK3	341 bp - 2030 bp (NM_002756)
SRPK-2	1238 bp - 2790 bp (U88666)

[0067] The nucleoside sequences of the genes coding for the human cellular protein kinases RICK, RIP, NIK, MKK3, and SRPK-2 listed in Table 3 together with the amino acid sequences of said enzymes can be obtained from NCBI (National Library of Medicine: PubMed; Web address: www.ncbi.nlm.nih.gov/entrez). Sequence protocols of the five cellular protein kinases are attached to this application as a part of the description.

[0068] The polypeptide product of gene expression may be assayed to determine the amount of expression as well. Methods for assaying for a protein include, but are not limited to, Western blot, immunoprecipitation, radioimmunoassay and peptide immobilization in an ordered array. It is understood, however, that any method for specifically and quantitatively measuring a specific protein or mRNA product can be used.

[0069] A variety of supports upon which nucleic acids or peptides can be immobilized are known in the art, for example filters, or polyvinyl chloride dishes. Any solid surface to which oligonucleotides or peptides can be bound, either directly or indirectly, either covalently or non-covalently, can be used. A preferred solid support is a microarray membrane filter or a "biochip". These contain particular polymer probes in predetermined locations on the array. Each predetermined location may contain more than one molecule of the probe, but each molecule within the predetermined location has an identical sequence.

[0070] The present invention incorporates by reference in their entirety techniques well known in the field of molecular biology. These techniques include, but are not limited to, techniques described in the following publications:

Ausubel, F.M. et al. eds., Short Protocols In Molecular Biology (4th Ed. 1999) John Wiley & Sons, NY. (ISBN 0-471-32938-X).

Old, R.W. & S.B. Primrose, Principles of Gene Manipulation: An Introduction To Genetic Engineering (3d Ed. 1985) Blackwell Scientific Publications, Boston. Studies in Microbiology; V.2:409 pp. (ISBN 0-632-01318-4).

Miller, J.H. & M.P. Calos eds., Gene Transfer Vectors For Mammalian Cells (1987) Cold Spring Harbor Laboratory Press, NY. 169 pp. (ISBN 0-87969-198-0).

Mayer, R.J. & J.H. Walker eds., Immunochemical Methods In Cell and Molecular Biology (1987) Academic Press, London. 325 pp. (ISBN 0-12480-855-7).

Sambrook, J. et al. eds., Molecular Cloning: A Laboratory Manual (2d Ed. 1989) Cold Spring Harbor Laboratory Press, NY. Vols. 1-3. (ISBN 0-87969-309-6).

Winnacker, E.L. From Genes To Clones: Introduction To Gene Technology (1987) VCH Publishers, NY (translated by Horst Ibelgauffs). 634 pp. (ISBN 0-89573-614-4).

[0071] The present invention further incorporates by reference in their entirety techniques well known in the field of microarray construction and analysis. These techniques include, but are not limited to, techniques described in the following patents and patent applications describing arrays of biopolymeric compounds and methods for their fabrication: U.S. Pat. Nos. 5,242,974; 5,384,261; 5,405,783; 5,412,087; 5,424,186; 5,429,807; 5,436,327; 5,445,934; 5,472,672; 5,527,681; 5,529,756; 5,545,531; 5,554,501; 5,556,752; 5,561,071; 5,599,895; 5,624,711; 5,639,603; 5,658,734; 5,807,522; 6,087,102; WO 93/17126; WO 95/11995; WO 95/35505; EP 742 287; and EP 799 897. Techniques also include, but are not limited to, techniques described in the following patents and patent application describing methods of using arrays in various applications: U.S. Pat. Nos. 5,143,854; 5,288,644; 5,324,633; 5,432,049; 5,470,710; 5,492,806; 5,503,980; 5,510,270; 5,525,464; 5,547,839; 5,580,732; 5,661,028; 5,994,076; 6,033,860; 6,040,138; 6,040,140; WO 95/21265; WO 96/31622; WO 97/10365; WO 97/27317; EP 373 203; and EP 785 280.

[0072] It is readily apparent to those skilled in the art that other suitable modifications and adaptations of the com-

positions and methods of the invention described herein are obvious and may be made without departing from the scope of the invention or the embodiments disclosed herein. Having now described the present invention in detail, the same will be more clearly understood by reference to the following examples, which are included for purposes of illustration only and are not intended to be limiting of the invention.

Examples

Materials and Methods

EXAMPLE 1:

Signal Transduction cDNA Microarray Construction

[0073] To study the cellular pathology associated HCMV, a unique microarray of more than 1100 signal transduction cDNAs was created.

[0074] In order to manufacture cDNA-arrays on membranes, the following strategy was employed: cDNAs encoding parts of or full length proteins of interest (referred to as "target cDNAs") were cloned into the plasmid BLUESCRIPT II KS⁺ (Stratagene, USA). Large scale purifications of these plasmids were performed according to standard techniques, and 200 μ l aliquots (1 μ g/ μ l plasmid concentration) were transferred into appropriate 96 well plates. The plates were then sealed with sealing tape, incubated for 10 minutes at 95°C, and chilled on ice for 5 minutes. 10 μ l of 0.6N NaOH were added, and the mix was then stored for 20 minutes at room temperature. Following the incubation at room temperature, 10 μ l 2.5M Tris-HCl (Tris-(hydroxymethyl)-aminomethane-hydrochloride) pH7.1 and 20 μ l 40x SSC (6M Sodium chloride - 0.6M tri-Sodium citrate buffer) was added.

[0075] Target cDNAs were spotted onto Nylon or Nitrocellulose membranes using a BIOGRID (BioRobotics, UK) equipped with a 0.7mm pintool. 200-350ng of plasmid-encoding target cDNAs were transferred onto the membranes and crosslinked to the membranes using ultraviolet light (1.2x10⁵ μ J/cm²) treatment. The arrays were stored for use in subsequent experiments (described below) at room temperature.

EXAMPLE 2:

HCMV Infection

[0076] To examine the effects of HCMV infection on cellular signal transduction activity, HCMV-infected cells were generated for comparison to control (i.e., uninfected) cells.

[0077] Primary human foreskin fibroblasts (HFF) were grown close to confluency in MEM medium (Minimum Essential Medium, Life Technologies) supplemented with 20% fetal calf serum at 37°C and 5% CO₂ to obtain ~6x10⁶ cells per tissue culture flask. Virus adsorption to the cells was performed with the HCMV strain AD169 at different (0.2, 1, and 3) multiplicities of infection (MOI) for 90 minutes in a volume of 5ml at 37°C. The viral inoculum was removed, and cells were cultured in 50ml of MEM medium supplemented with 20% fetal calf serum and 150 μ g/ml cycloheximid at 37°C and 5%CO₂ for 7, 24, 48, or 72 hours, respectively.

EXAMPLE 3:

Isolation and Purification of Poly A⁺ RNA

[0078] In order to perform differential expression analysis using the cDNA microarray described in Example 1, RNA extraction and purification on the HCMV-infected and uninfected cells was performed using techniques known in the art.

[0079] Briefly, after incubation (for the respective time-intervals) of infected and control cells, cells were washed twice with phosphate buffered saline (PBS) and then trypsinized. Cells were removed from the culture dish by resuspension with PBS. Cells were then sedimented, and directly lysed by repetitive pipetting in 1ml of Tri reagent (Molecular Research Centre, Inc., USA) per 1x10⁶ cells.

[0080] Cell lysates were stored at room temperature for 5 minutes, and then centrifuged (12,000xg) for 15 minutes at 4°C. The supernatant was mixed with 0.1ml of 1-bromo-3-chloropropane per 1ml of Tri reagent and shaken vigorously. The resultant suspension was stored for 5 minutes at room temperature, and then centrifuged (12,000xg) for 15 minutes at 4°C.

[0081] Following centrifugation, the colorless upper phase was transferred into new tubes, mixed with 5 μ l of polyacryl-carrier (Molecular Research Centre, Inc., USA), and vigorously shaken with 0.5ml of isopropanol per 1ml of Tri reagent. The samples were stored at room temperature for 5 minutes and then centrifuged (12,000xg) for 8 minutes

at 4°C. The supernatant was removed and the RNA pellet washed twice with 1ml of 75% ethanol. The pellet was dried and resuspended in RNase-free buffer at a concentration of 1µg RNA per 1µl buffer.

[0082] Purification of poly A⁺ RNA from total RNA was performed using the OLIGOTEX system (Qiagen, Germany) following manufacturer's instructions. In brief, 100-200µg of total RNA was brought up to 250µl with RNase-free water, and 250µl of buffer OBB (20mM Tris/HCl pH7.5, 1M NaCl, 2mM EDTA, 0.2% SDS) and 15µl of OLIGOTEX suspension was added. The samples were incubated for 3 minutes at 70°C, and placed at room temperature for 10 minutes. The samples were centrifuged for 2 minutes (12,000xg), and the supernatant removed. The remaining pellet was resuspended in 400µl buffer OW2 (10mM Tris/HCl pH7.5, 150mM NaCl, 1mM EDTA). The suspension was transferred to a spin column (supplied with the system) and centrifuged at 12000xg for 1 minute at room temperature. The spin column was transferred to a new tube and 400 µl of buffer OW2 was applied on the column. The spin column was centrifuged (12,000xg) for 1 minute at room temperature. The spin column was transferred to a new tube and the RNA eluted from the column by the addition of 50µl buffer OEB (5mM Tris/HCl pH7.5) (at 70°C) to the column, resuspension of the Oligotex-resin, and centrifugation (12,000xg) for 1 minute at room temperature.

[0083] Any genomic DNA contamination of the RNA preparations was eliminated by enzymatic digestion using DNase I. 6µl of 10x DNase buffer (Promega, USA) and 4µl of RQ-DNase (Promega, USA) were added to 50µl of the RNA-buffer solution, and the reaction mixture was incubated for 15 minutes at 37°C. Stop-buffer (6µl; Promega, USA) was then added, the mixture brought to 200 µl final volume with TE buffer (10mM Tris/HCl, 1mM EDTA), and Phenol/Chloroform extractions were performed twice. The RNA-containing phase was transferred to new reaction tubes and RNA was precipitated using 5M NaCl (final concentration of 0.2M), 1µl poly-acryl-carrier (Molecular Research Centre, Inc., USA) and 500 µl of 100% ethanol. The solution was centrifuged for 10 minutes at 4°C, the RNA pellet washed with 1ml of 80% ethanol, dried, and resuspended in 30µl TE buffer. Poly A⁺ RNA suspension samples were stored at -70°C for use in subsequent experiments.

EXAMPLE 4:

Preparation of Radioactively Labeled cDNA Probes from RNA

[0084] To prepare test and control samples for microarray analysis, RNA samples isolated and purified from HCMV-infected and control cells (prepared as described in Example 3) were used to generate radioactively labeled cDNA probe. Many techniques to generate labeled cDNA constructs from cellular RNA extracts are known in the art and applicable to the present invention. Two of those protocols were used in this example to generate radiolabeled cDNA from RNA samples: the first technique involved reverse transcribing cDNA from the RNA sample in the presence of radioactively labelled dATP; the second technique involved first strand cDNA synthesis from the RNA sample, followed by random priming with radioactively labelled dATP.

[0085] For reverse transcription of cDNA from the RNA sample in the presence of radioactively labelled dATP, 1µg of primer TXN (5'-TTT TTT TTT TTT TXN-3'; SEQ ID NO:1; with T = dTTP; N = dATP, dCTP, dGTP or dTTP; X = dATP, dCTP or dGTP) and total RNA (1 to 15 µg) or poly A⁺ RNA (20 to 500 ng) were combined in 12 µl bidistilled DEPC-treated H₂O (DEPC: diethylpyrocarbonate) and shaken for 5-15 minutes at 60°C. The mixture was then incubated at 4°C for 2-10 minutes, and centrifuged (10,000xg) for 30 seconds.

[0086] After centrifugation, 7µl of a labelling mix (100µCi γ[³²P]-ATP (Amersham, UK); vacuum dried and resuspended in 4µl first strand buffer (Life Technologies, USA); 2µl 0.1M DTT (dithiothreitol); and 1µl labelling solution -- 4mM dCTP, dGTP, dTTP each and 80 µM dATP final concentration) was added to the RNA solution. 1µl SUPERScript II reverse transcriptase (Life Technologies, USA) was added and the reaction incubated for 10 minutes at room temperature and then for 60 minutes at 38°C. Following the reaction incubation, 5µl 0.5M EDTA (ethylene diamine tetraacetate) and 25 µl 0.6M NaOH was added to the reaction mixture and shaken vigorously for 30 minutes at 68°C.

[0087] Unincorporated nucleotides were removed from the labelling reaction using PROBEQUANT G-50 columns (Amersham, UK). The column (with bottom closure and lid removed) was shaken vigorously and centrifuged (735xg) for 1 minute in an appropriate reaction tube. The column was placed into a new reaction tube, the probe was applied onto the center of the column material and the column was centrifuged (735xg) for 2 minutes. The flow-through was transferred into new reaction tubes and bidistilled H₂O added to 100 µl final volume. 5M NaCl, 1µl poly-acryl-carrier (Molecular Research Centre, Inc., USA) and 250 µl ethanol was added, and the probe precipitated by centrifugation (12,000xg) for 15 minutes. The supernatant was discarded and the pellet dried for subsequent use.

[0088] For the alternate labelling technique (random priming with radioactively labelled dATP after first strand cDNA synthesis), the following procedure was followed: 1µg primer TXN (see above) was added to 20-500ng of poly A⁺ RNA in 12 µl final volume, incubated for 5 minutes at 60°C, followed by an addition incubation for 2-10 minutes on ice. The mix was centrifuged (12,000xg) for 30 seconds, and 4µl of first strand buffer (Life Technologies, USA), 2µl 0.1M DTT, 1µl 10mM dNTP and 1µl SUPERScript II reverse transcriptase (Life Technologies, USA) was added. The reaction was incubated for 10 minutes at room temperature, followed by an additional incubation for 60 minutes at 38°C. Fol-

lowing the reaction incubation, 5µl 0.5M EDTA and 25 µl 0.6M NaOH was added to the reaction mixture and shaken vigorously for 30 minutes at 68°C.

[0089] Unincorporated nucleotides were removed as described above; however, the final pellet was resuspended in 30µl bidistilled H₂O.

[0090] 15 µl of the resuspended cDNA solution was transferred to new reaction tubes, incubated for 5 minutes at 95°C, chilled on ice for 5 minutes, and centrifuged for 30 seconds. Following manufacturer's instructions accompanying the Random Primers DNA Labelling system (Life technologies, USA), 15 µl buffers mixture, 2µl of each dCTP, dGTP and dTTP (provided with the system) were added to the cDNA. 5µl γ[³³P]-ATP (Amersham, UK) was added and the mixture adjusted to 49µl final volume with bidistilled H₂O. The reaction was started by addition of 1µl Klenow enzyme (supplied with the system), and incubated for 60 minutes at 25°C 5µl. Stop solution (provided with the system) was added and unincorporated nucleotides were removed by column purification as described above.

EXAMPLE 5:

Hybridization of Labeled cDNA Probe to cDNA Array

[0091] To screen HCMV-infected cells compared to uninfected cells for differential activation of cellular signal transduction, labeled cDNA probes (generated according to Example 4) were exposed to a signal transduction cDNA microarray (generated as described in Example 1) following hybridization techniques known in the art.

[0092] Sample pellets from Example 4 were resuspended in 10µl C₆T DNA (1µg/µl, Roche Diagnostics, Germany), 10µl yeast tRNA (1µg/µl Sigma, USA) and 10µl poly A (1µg/µl, Roche Diagnostics, Germany). Herring sperm DNA (to a final concentration of 100µg/ml), 5µl 10% SDS (Sodiumdodecylsulfate), and 25 µl 20x SSPE was added, and adjusted 100µl final volume with bidistilled H₂O. The mix was incubated for 5 minutes at 95°C, centrifuged (10,000xg) for 30 seconds, and vigorously shaken for 60 minutes at 68°C. A 1µl aliquot of the probe was used to measure the incorporation of radioactive dATP with a scintillation counter. Probes with at least a total of 20x10⁶ cpm were used for the screen assay.

[0093] Arrays were prehybridized in hybridization solution for at least 30 minutes in a roller bottle oven at 42°C. Following prehybridization, radiolabelled probe was added to the hybridization solution and hybridization was continued for 20-40 hours.

[0094] Following hybridization, the probe was discarded and the array subjected to a series of washes. Initially the arrays were washed twice in wash solution A (2xSSC) in the roller oven at room temperature. Wash solution A was then replaced with wash solution B (2x SSC, 0.5% SDS), preheated to 60°C, and arrays were washed twice for 30 minutes at 60°C. Wash solution B was then replaced with wash solution C (0.5x SSC, 0.5% SDS), preheated to 60°C, and arrays were washed twice for 30 minutes at 60°C.

[0095] The moist arrays were wrapped in airtight bags and exposed for 8-72 hours on erased phosphorimager screens (Fujifilm, Japan).

EXAMPLE 6:

Signal Transduction cDNA Array Analysis

[0096] To demonstrate differential activation of cellular signal transduction in HCMV-infected cells compared to uninfected cells, hybridized cDNA arrays from infected and uninfected samples were analyzed.

[0097] Exposed phosphorimager screens (from Example 5) were scanned with a resolution of 100µ and 16bits per pixel using a BAS-1800 (Fujifilm, Japan). The data were imported into the computer program, ARRAYVISION (Imaging Research, Canada), and analyzed according the computer program's specification. Hybridization signal strength is indicative of the quantity of RNA molecules present in the probe. Differentially expressed genes were identified according to the ratio of signal strength after normalization to the overall intensity of the arrays.

[0098] Signal transduction cDNA microarray analysis of radiolabelled cDNA-probes from HCMV-infected (strain AD169) versus non-infected primary human foreskin fibroblasts to cDNA-arrays revealed significant upregulation of the cellular kinase cDNAs:

RICK (2-fold at 3 hours post infection; 3.6-fold at 7 hours post infection);
RIP (2.6-fold at 3 hour post infection; 2.2-fold at 24 hour post infection);
NIK (4-fold at 7 hour post infection);
MKK3 (2-fold at 3 hour post infection; 2.5-fold at 7 hour post infection); and
SRPK-2 (2.2-fold at 7 hour post infection)

compared to uninfected human foreskin fibroblasts cells.

EXAMPLE 7:

Northern Blot Analysis

[0099] To confirm the results of the microarray analysis of Example 6, northern blot analysis was performed according to techniques well known in the art.

[0100] HCMV-infected and uninfected cells (from Example 2) cells were pelleted and the total RNA was prepared as follows: Following centrifugation and removal of the supernatant, cells were lysed in 1ml of Trizol reagent (ready-to-use-reagent from Gibco-BRL) per 1.5×10^6 cells. The Tri reagent/cell lysate was transferred to an eppendorff tube and centrifuged (13,000rpm) for 15 minutes at 4°C. The supernatant was transferred to a new eppendorff tube and 0.1ml of BCP (1-bromo-3-chloropropane) for each ml of Tri reagent was added. Samples were vortexed for 15 seconds, incubated for 5 min at room temperature, and then centrifuged (13,000rpm) for 15 minutes at 4°C. The upper aqueous phase was transferred to a new eppendorff tube, 0.5 ml isopropanol was added for each ml of Tri reagent (Molecular Research Center, Inc., USA), vortexed, and incubated for additional 8 min at room temperature, and centrifuged (13,000rpm) for 10 min at 4°C. The supernatant was aspirated, and the precipitated RNA was washed twice with ice-cold 75% ethanol and air-dried. The RNA pellet was resuspended in 50µl Tris-HCl pH 7.5.

[0101] The quantity of the RNA for each sample was determined by UV-spectroscopy, and the quality was determined via gel electrophoresis on a formaldehyde-containing 1.2% agarose gel.

[0102] RNA samples of 10µg each were size-fractionated by 1.2% formaldehyde agarose gel electrophoresis and transferred to synthetic membrane filters (Hybond N, Amersham) with 20XSSC (1 X SSC is 150 mM NaCl, 15 mM $C_6H_5Na_3O_7 \times 2H_2O$, pH 7.0) overnight. RNA was immobilized to the filter using UV-light for crosslinking (120 mJ/cm² for 25 seconds).

[0103] Membrane filters were firstly prehybridized for 4 hours at 65°C in a prehybridization solution containing 5 X SSC, 10 X Denhardt's solution (1 X Denhardt's solution is 0.02% bovine serum albumine, 0.02% polyvinyl pyrrolidone, 0.02% ficoll), 20mM sodium phosphate, pH 7.0, 7% SDS, 100µg/ml sonicated salmon sperm DNA, and 100µg/ml. Hybridization was performed at 65°C in the prehybridization buffer containing 10% dextran sulphate, plus added radiolabelled probe for 16 hours.

[0104] Membrane filters were hybridized to oligonucleotide probes specific for a particular cellular kinase identified in Example 6. Probes sequences included the following:

Table 4:

Cellular Kinase	cDNA Probe Sequence	SEQ ID NO:
NIK	5'- GTC CTG GAG GGC TCT TTT TGA TGA AAC C - 3'	2
RIP	5'- GTG CTC AAT GCA GTT GGG CCC CTT GTA CAC-3'	3
RICK	5'- GTC GAG CAG CGG AGT GTG GAT GTG CAG - 3'	4

[0105] The oligonucleotides were radiolabelled at their 3' ends with (alpha-32P) deoxyadenosine 5'- triphosphate (³²P-α-dATP) (Amersham) employing the Terminal Transferase kit (Roche) following manufacturer's instructions.

[0106] Unincorporated ³²P-α-dATP nucleotides were removed similar to the protocol described in Example 4: After vortexing the PROBEQUANT Sephadex G-50 (Amersham, UK) column (with bottom closure and lid removed), the column was placed in a 2 ml tube and centrifuged for 1 minute at 735xg. The column was placed in a new 1.5ml eppendorff tube (without a cap), and the radioactive probe was pipetted carefully on the center of the preformed resin. Centrifugation (735xg) for 2 minutes effectively removed the unincorporated ³²P-α-dATP nucleotides.

[0107] Hybridized filters were washed once in 5% SDS, 3 X SSC, 10 X Denhardt's solution, 20mM sodium phosphate, pH 7.0 for 30 min at 65°C. A second wash step followed in 1 X SSC, 1% SDS at 65°C for 30 min.

[0108] Filters were exposed at -80°C to Kodak XAR-5 films using intensifying screens.

[0109] Northern blot analysis confirmed upregulation of cellular kinase mRNA: RICK, RIP, and NIK in HCMV-infected cells compared to uninfected cells, consistent with results obtained from microarray analysis.

EXAMPLE 8:

Western Blot Analysis

[0110] To further confirm the results of the microarray analysis of Example 6 and northern blot analysis of Example 7, western blot analysis was performed according to techniques well known in the art.

[0111] HCMV-infected and uninfected cells (from Example 2) were pelleted and polypeptide extracts prepared as follows: Infected and uninfected cell samples (from various time intervals) were lysed with 420 μ l of lysis buffer (20mM Hepes (N-[2-hydroxyethyl]piperazine-N'-[2-ethansulfonic acid]) pH7.5, 150 mM NaCl, 1% TRITON X-100 (t-octylphenoxypolyethoxyethanol), 10% glycerol, 1mM PMSF (phenylmethylsulfonyl fluoride), 10 μ g/ml Aprotinin, 1mM orthovanadate) on ice. Lysed cells were cleared from debris by centrifugation (15 minutes, 13000 rpm, 4°C), dissolved in 1x Laemmli buffer, denatured for 5 minutes at 100°C and submitted to SDS-PAGE (gradient gel 7% - 12%).

[0112] Gels were blotted onto nitrocellulose filters (Amersham, UK) for 3 hours (0.8mA/cm²). Detection of expression of the identified host cell kinases was performed using the following target specific antibodies: OPA1-01023 polyclonal rabbit anti-RICK antibody (Dianova); H-207 polyclonal rabbit anti-RIP antibody (Santa Cruz Biotechnology); I-20 polyclonal rabbit anti-MKK3 antibody (Santa Cruz Biotechnology); S80620 murine anti-SRPK2 antibody (Transduction Laboratories); anti-NIK rabbit serum (generated by SIGMA Genosys Biotechnologies using the NIK-peptide 5'-CNPT-NTRPQSDTPEIRKYKKRFN-3', SEQ ID NO:5, for immunization). All antibodies were used according to the manufacturer's instructions. Detections were performed with the ECL Kit (Amersham, UK).

[0113] Western blot analysis confirmed the transcriptional upregulation of infected host cell kinase mRNAs resulted in increased expression of the respective proteins:

- A single ~60kDa band representing RICK was upregulated between 7-24 hours post HCMV infection;
- A single ~74kDa band representing RIP was upregulated between 7-72 hours post HCMV infection;
- A single ~135kDa band representing NIK was upregulated between 24-72 hours post HCMV infection;
- A single ~35kDa band representing MKK3 was upregulated between 7-72 hours post HCMV infection; and
- A single ~115kDa band representing SRPK2 was upregulated between 24-72 hours post HCMV infection.

EXAMPLE 9:

Genetic Validation

[0114] HFF cells were infected with Adenovirus expressing various kinase constructs at different particles per cell ratios (p/c). The adenovirus used here were all E1, E3 defective derivatives of adenovirus type 5 (reviewed in Russell WC (2000) Update on adenovirus and its vectors. J Gen Virol. 81:2573-604). Briefly, the cDNA of interest was cloned into a transfer plasmid bearing the CMV IE promoter enhancer (IE: immediate early) and the rabbit beta-globin intron/polyadenylation signal. This expression cassette was inserted into a bacterial plasmid borne-adenovirus genome using recombination in bacteria (Chartier C., E. Degryse, M. Gantzer, A. Dieterle, A. Pavirani, and M. Mehtali. 1996. Efficient generation of recombinant adenovirus vectors by homologous recombination in *Escherichia coli*. J. Virol. 70: 4805-4810.). Virus was amplified in HEK 293 cells and purified from cell lysates using CsCl density gradient centrifugation as described (Cotten, M., Baker A., Birnstiel M.L., Zatloukal, K., Wagner, E. (1996) Adenovirus polylysine DNA conjugates. in Current Protocols in Human Genetics, Eds. N. C. Dracopoli, J. L. Haines, B.R. Korf, D.T. Moir, C.C. Morton, C.E. Seidman, J.G. Seidman, D.R. Smith; John Wiley and Sons, Inc. New York. pp. 12.3.1-12.3.33.). The control viruses AdJ5 was previously described (Glotzer J.B., Saltik M., Chiocca S., Michou A.I., Moseley P. and Cotten M. (2000) Activation of heat-shock response by an adenovirus is essential for virus replication. Nature 407:207-11).

[0115] Two days after plating HFF cells, cultures were infected with CMV strain Ad169-GFP. Replication of CMV was estimated after one week (7 dpi) utilizing the GFP-signal expressed as GFP counts.

[0116] Fig. 1 shows the reduction rates in HCMV replication of HFF cells pre-infected with Adeno virus containing the RIP wildtype sequence (AdRIPwt; 1 - 4) and a RIP inactive mutant (AdRIPkr; 5 - 8).

[0117] No HCMV-infection resulted in hardly any signal (mock, 13), while infection with HCMV yielded in about 13.000 GFP counts (AD169-GFP; 14). Pre-infection with increasing amounts of control Adeno virus (AdliteJ5) caused a slight reduction in HCMV replication (9 - 12). There was a clear difference, when HFF cells were pre-infected with Adeno virus containing the RIP wildtype sequence (AdRIPwt; 1 - 4) and a RIP inactive mutant (AdRIPkr; 5 - 8). The lysine (K) at amino acid position 45 is mutated to an arginine (R), which renders the kinase inactive. This mutation was introduced into the human RIP cDNA utilizing the QuikChange™ Site-directed Mutagenesis Kit (Stratagene, CA, USA) according to the instructions of the manufacturer. Expression of the mutated RIP kinase efficiently blocked HCMV replication (5 - 8), while the wildtype sequence was less potent in doing so (1 - 4).

[0118] Fig. 2 shows the reduction rates in HCMV replication of HFF cells pre-infected with Adeno virus containing

the RICK wildtype sequence (AdRICKwt) and two RICK inactive mutants (AdRICKkr and AdRICKdn). In one construct (AdRICKkr), the lysine (K) at position 47 is mutated to an arginine (R). In the other construct (AdRICKdn), the aspartate at position 146 is mutated to an asparagine. Both changes in sequence render the kinase inactive. The mutations were introduced into the human RICK cDNA utilizing the QuikChange™ Site-directed Mutagenesis Kit (Stratagene, CA, USA) according to the instructions of the manufacturer.

[0119] Similar experiments as described for RIP (Example 9, Fig. 1) were also performed with RICK. No HCMV-infection resulted in hardly any signal (Mock + Mock), while infection with HCMV yielded in about 7.000 GFP counts (Mock + AD169-GFP). Pre-infection with increasing amounts of control Adeno virus (AdliteJ5, from 111 to 3000 particles per cell) caused a slight reduction in HCMV replication. There was a clear difference, when HFF cells were pre-infected with Adeno virus containing the RICK wildtype sequence (AdRICKwt) and two RICK inactive mutants (AdRICKkr and AdRICKdn). All three RICK constructs efficiently reduced HCMV-replication.

EXAMPLE 10:

RICK-Kinase Assay

[0120] To obtain active RICK kinase the human RICK-cDNA was fused with a DNA sequence coding for the HA-tag and cloned into the eucaryotic expression vector pcDNA3 (Invitrogene). This construct was transfected into human embryonic kidney cells (HEK 293) via the calcium-phosphate co-precipitation method. One day after transfection medium was replaced by fetal calf serum-free medium and two days after transfection cells were washed with PBS and harvested and lysed in RIPA-buffer (150 mM NaCl, 1 mM EDTA, 1% Tritron X-100, 1% Na-desoxycholate, 0.1 % SDS, 10 mM Tris-HCl pH 7.5). The RICK-HA fusion protein was immunoprecipitated from 250 µl cleared lysate (i.e. lysate of one well of a six-well plate) utilizing an anti-HA antibody from Roche Pharmaceuticals and Protein A sepharose. After addition of 500 µl of HNTG-buffer (50 mM HEPES pH 7.5, 150 mM NaCl, 1 mM EDTA, 10% glycerine, 0.1% Triton X-100) the sample was rotated for 3 hrs at 4°C. After washing the immunoprecipitate twice with 0.5 ml HNTG-buffer and twice with 0.5 ml assay-buffer (25 mM Tris-HCl pH 7.5, 3 mM MgCl₂, 0.5 mM MnCl₂, 0.5 mM DTT and 50 mM NaCl), the kinase reaction was performed directly on the beads in 40 µl assay buffer containing 2.5 µCi γ[³²P]-ATP and various concentrations (between 100 nM and 50 µM) of compounds of Table 1. After 30 min at 30°C, the reaction was stopped by addition of 40 µl 3X Laemmli-buffer (16% glycerol, 1.01M β-mercaptoethanol, 5% SDS, 200mM Tris/HCl pH 6.8, 8% bromphenolblue). Phosphorylation products were analyzed by SDS-PAGE and autoradiography (x-ray film and phosphor imager).

EXAMPLE 11:

RIP-Kinase Assay

[0121] To obtain active RIP kinase the human RIP-cDNA was fused with a DNA sequence coding for the HA-tag and cloned into the eucaryotic expression vector pcDNA3 (Invitrogene). This construct was transfected into human embryonic kidney cells (HEK 293) via the calcium-phosphate DNA co-precipitation method. Two days after transfection cells were washed with PBS and harvested and lysed in lysis-buffer (150 mM NaCl, 1 mM EDTA, 1% Tritron X-100, 20 mM Tris-HCl pH 7.5 and freshly added: 30 mM NaF, 10 µg/ml Aprotinine, 10 µg/ml Leupeptine, 2 mM Na-pyrophosphate). The RIP-HA fusion protein was immunoprecipitated from 250 µl cleared lysate (i.e. lysate of one well of a six-well plate) utilizing an anti-HA antibody from Roche Pharmaceuticals and Protein A sepharose. The sample was rotated for 3 hrs at 4°C. The immunoprecipitates were washed twice with 0.75 ml lysis-buffer, twice with 0.75 ml high salt-buffer (1 M NaCl, 1 mM EDTA, 1% Tritron X-100, 20 mM Tris-HCl pH 7.5 and freshly added: 30 mM NaF, 10 µg/ml Aprotinine, 10 µg/ml Leupeptine, 2 mM Na-pyrophosphate), twice with 0.75 ml lysis-buffer and twice 0.75 ml with kinase assay buffer (10 mM MgCl₂, 10 mM MnCl₂, 10 mM benzamidine, 0.5 mM EDTA). The kinase reaction was performed directly on the beads in 40 µl kinase assay buffer containing 2.5 µCi γ[³²P]-ATP and various concentrations (between 100 nM and 50 µM) of compounds of Table 2. After 30 min at 30°C, the reaction was stopped by addition of 40 µl 2X Laemmli-buffer. Phosphorylation products were analyzed by SDS-PAGE and autoradiography (x-ray film and phosphor imager).

EXAMPLE 12:

Virus Replication Assay

Cell culture and virus

[0122] Primary human foreskin fibroblasts (HFF) were cultivated in MEM containing 5% (v/v) fetal calf serum. Infec-

tion analysis was restricted to cell passage numbers below twenty. Human cytomegalovirus strain AD169 (ATCC) was grown in HFF cells and quantitated for infectivity by the plaque reduction assay. Aliquots were stored at -80°C.

Construction of recombinant cytomegalovirus

[0123] For construction of a recombination vector, two linker sequences were inserted into the pBlueScribe vector pBS+ (Stratagene): the first contained restriction sites for NheI, SpeI, PaeI and BglI followed by a loxP sequence (ATAACTTCGTATAGCATACATTATACGAAGTTAT) and was introduced into PstI/XbaI sites of the vector; the second contained another loxP sequence followed by restriction sites HpaI, ClaI and PmeI and was introduced into BamHI/Asp718 sites. A gene cassette comprising of a "humanized" version of the ORF coding for GFP (gfp-h) under the control of the HCMV enhancer/promoter and the Ptk/PY441 enhancer-driven neoR selection marker was excised from plasmid pUF5 (Zolotukhin et al., 1996, J. Virol. 70, 4646-4654) and inserted into the recombination vector via BglII sites.

[0124] At the 5' and 3'-positions of this loxP-flanked gene cassette, two HCMV sequences with homology to the gene region containing the open reading frames US9 and US10 were inserted. For this, viral sequences were amplified from template pCM49 (Fleckenstein et al., 1982, Gene 18, 39-46) via PCR in a 35-cycle program (denaturation 45 sec at 95°C, annealing 45 sec at 55°C and elongation 2 min at 72°C) by the use of Vent DNA polymerase (New England Biolabs). A US10-specific sequence of 1983 bp in length was generated using primers US10[200900]SpeI (GCT-C**ACTAGT**GGCCTAGCCTGGCTCATGGCC) and US10[198918]PaeI (GTCCT**TAA**TTAAGACGTGGTTGTGGTCAC-CGAA) and inserted at the vector 5' cloning position via SpeI/PaeI restriction sites (see bold-print). A US9-specific sequence of 2010 bp was generated using primers US9-3'PmeI (CTCGG**TTAA**ACGACGTAGGCGCTCCGTCACC) and US-5' ClaI (TTGC**ATCG**ATACGGTGTGAGATACCACGATG) inserted at the vector 3' cloning position via PmeI/ClaI restriction sites.

[0125] The resulting construct pHM673 was linearized by the use of restriction enzyme NheI and transfected into HEF cells via the electroporation method using a Gene Pulser (Bio-rad; 280 V, 960 µF, 400 Ω). After 24 h of cultivation, cells were used for infection with 1 PFU/ml of HCMV strain AD169. Selection with 200 µg/ml G418 was started 24 h post infection. Following 3 weeks of passage in the presence of G418, GFP fluorescence could be detected in most of the infected cells. Plaque assays were performed with infectious culture supernatant on HFF cells and single virus plaques were grown by transfer to fresh HFF cells cultured in 48-well plates. DNA was isolated from cells of 32 fluorescence-positive wells and confirmed for the presence of recombinant virus by PCR. For this, primers US9[198789] (TGACGCGAGTATTACGTGTC) and US10[199100] (CTCCTCCTGATATGCGGTT) were used resulting in an amplification product of 312 bp for wild-type AD169 virus and approximately 3.5 kb for recombinant virus.

Plaque assay

[0126] HFF cells were cultivated in 12-well plates to 90-100% confluency and used for infection with dilutions of virus-positive cell culture supernatants. Virus inoculation was performed for 90 min at 37°C under occasional shaking before virus was removed and the cell layers were rinsed with PBS. Overlays of MEM 5% (v/v) fetal calf serum and 0.3% (w/v) agarose were added to each well and all samples were incubated at 37°C in a 5% CO₂ atmosphere for approximately 12 days. Finally, overlays were removed and the formation of foci was visualized by staining with 1 % crystal violet in 20% ethanol for 1 min. After repeated rinsing with PBS, plates were air-dried at room temperature and plaque numbers were counted with a light microscope. For the recombinant AD169-GFP virus, quantification of plaque assays could also be performed without crystal violet staining by a direct counting of the amount of green fluorescent plaques using fluorescence microscopy.

Antiviral compounds

[0127] The reference compounds used for antiviral studies, ganciclovir (GCV, Cymeven), foscarnet sodium (FOS, Foscavir) and cidofovir (CDV, Vistide) were purchased from Syntex Arzneimittel (Aachen, Germany), Sigma-Aldrich (Germany) and Pharmacia & Upjohn S.A. (Luxembourg), respectively. Stocks were prepared in aqueous solution and stored at -20°C. The test compounds were dissolved in DMSO and aliquots were stored at -20°C.

GFP infection assay

[0128] HFF cells were cultivated in 12-well plates to 90-100% confluency and used for infection with 0.5xTCID₅₀ of AD169-GFP virus. Virus inoculation was performed for 90 min at 37°C with occasional shaking before virus was removed and the cell layers were rinsed with PBS. Infected cell layers were incubated with 2 ml of MEM containing 5% (v/v) fetal calf serum and optionally of the respective test substances or DMSO as control. Infected cells were incubated at 37°C in a 5% CO₂ atmosphere for 7 days and harvested by trypsinization and centrifugation. 200 µl of lysis buffer (25

EP 1 201 765 A2

mM Tris pH 7.8, 2 mM DTT, 2 mM trans-1,2-diaminocyclohexane-N,N,N',N'-tetraacetic acid, 1% Triton X-100, 10% glycerol) was added to each cell pellet and lysis was achieved by incubation for 10 min at 37°C followed by a 30-min incubation at room temperature on a shaker. Lysates were centrifuged for 5 min at 15.000 rpm in an Eppendorf centrifuge to remove cell debris. Supernatants were transferred to an opaque 96-well plate for automated measuring of GFP signals in a Victor 1420 Multilabel Counter (Wallac). GFP units were converted to percent inhibition values relative to DMSO controls (set at 100% GFP expression).

Indirect immunofluorescence analysis

[0129] Cells were either grown on Lab-Tek Permanox slides (Nunc) or harvested from 6-well plates, spotted onto glass slides with marked rings (Medco) and fixed by a 15-min treatment with 3% formaldehyde in PBS followed by permeabilization for 15 min in 0.1% Triton X-100 in PBS at room temperature. Blocking was achieved by incubation with Cohn Fraction II/III of human gamma-globulin (Sigma; 2 mg/ml) for 30 min at 37°C. The IE1/IE2-specific primary antibody MAb810 (Chemicon International, Inc. CA, USA; dilution 1:10.000) was incubated for 90 min, the secondary antibody (tetramethyl rhodamine [TRITC]-coupled anti-mouse antibody, Dianova, dilution 1:100) for 45 min at 37°C before analysis by fluorescence microscopy. In addition to indirect TRITC staining of IE1/IE2 proteins, GFP signals could be detected directly via the fluorescence isothiocyanate (FITC) channel. Nuclear counterstaining was carried out using Vectashield mounting medium including DAPI (Vector Laboratories, Burlingame, CA).

EP 1 201 765 A2

SEQUENCE LISTING

5 <110> Axxima Pharmaceuticals AG
 <120> CELLULAR KINASES INVOLVED IN CYTOMEGALOVIRUS INFECTION
 AND THEIR INHIBITION
 <130> PA012EP
 10 <140>
 <141>
 <160> 2
 15 <170> PatentIn Ver. 2.1
 <210> 1
 <211> 2501
 <212> DNA
 <213> Homo sapiens
 20 <220>
 <221> CDS
 <222> (225)..(1847)
 <400> 1
 25 ggcaccagtc tetagaaaag aagtcagctc tggttcggag aagcagcggc tggcgtgggc 60
 catccgggga atgggcgccc tcgtgacctc gtgttcgggg gcaaaaaggg tcttgccggc 120
 ctcgctcgtg caggggcgta tctgggcgcc tgagcgcgca gtgggagcct tgggagccgc 180
 30 cgcagcaggg ggcacaccgc gaaccggcct ggcgcgcccg gacc atg aac ggg gag 236
 Met Asn Gly Glu
 1
 gcc atc tgc agc gcc ctg ccc acc att ccc tac cac aaa ctc gcc gac 284
 Ala Ile Cys Ser Ala Leu Pro Thr Ile Pro Tyr His Lys Leu Ala Asp
 5 10 15 20
 35 ctg cgc tac ctg agc cgc ggc gcc tct ggc act gtg tgc tcc gcc cgc 332
 Leu Arg Tyr Leu Ser Arg Gly Ala Ser Gly Thr Val Ser Ser Ala Arg
 25 30 35
 40 cac gca gac tgg cgc gtc cag gtg gcc gtg aag cac ctg cac atc cac 380
 His Ala Asp Trp Arg Val Gln Val Ala Val Lys His Leu His Ile His
 40 45 50
 act ccg ctg ctc gac agt gaa aga aag gat gtc tta aga gaa gct gaa 428
 Thr Pro Leu Leu Asp Ser Glu Arg Lys Asp Val Leu Arg Glu Ala Glu
 55 60 65
 att tta cac aaa gct aga ttt agt tac att ctt cca att ttg gga att 476
 Ile Leu His Lys Ala Arg Phe Ser Tyr Ile Leu Pro Ile Leu Gly Ile
 70 75 80
 50 tgc aat gag cct gaa ttt ttg gga ata gtt act gaa tac atg cca aat 524
 Cys Asn Glu Pro Glu Phe Leu Gly Ile Val Thr Glu Tyr Met Pro Asn
 85 90 95 100
 gga tca tta aat gaa ctc cta cat agg aaa act gaa tat cct gat gtt 572
 Gly Ser Leu Asn Glu Leu Leu His Arg Lys Thr Glu Tyr Pro Asp Val
 105 110 115
 55

EP 1 201 765 A2

	gct tgg cca ttg aga ttt cgc atc ctg cat gaa att gcc ctt ggt gta	620
	Ala Trp Pro Leu Arg Phe Arg Ile Leu His Glu Ile Ala Leu Gly Val	
5	120 125 130	
	aat tac ctg cac aat atg act cct cct tta ctt cat cat gac ttg aag	668
	Asn Tyr Leu His Asn Met Thr Pro Pro Leu Leu His His Asp Leu Lys	
	135 140 145	
10	act cag aat atc tta ttg gac aat gaa ttt cat gtt aag att gca gat	716
	Thr Gln Asn Ile Leu Leu Asp Asn Glu Phe His Val Lys Ile Ala Asp	
	150 155 160	
	ttt ggt tta tca aag tgg cgc atg atg tcc ctc tca cag tca cga agt	764
	Phe Gly Leu Ser Lys Trp Arg Met Met Ser Leu Ser Gln Ser Arg Ser	
15	165 170 175 180	
	agc aaa tct gca cca gaa gga ggg aca att atc tat atg cca cct gaa	812
	Ser Lys Ser Ala Pro Glu Gly Gly Thr Ile Ile Tyr Met Pro Pro Glu	
	185 190 195	
20	aac tat gaa cct gga caa aaa tca agg gcc agt atc aag cac gat ata	860
	Asn Tyr Glu Pro Gly Gln Lys Ser Arg Ala Ser Ile Lys His Asp Ile	
	200 205 210	
	tat agc tat gca gtt atc aca tgg gaa gtg tta tcc aga aaa cag cct	908
	Tyr Ser Tyr Ala Val Ile Thr Trp Glu Val Leu Ser Arg Lys Gln Pro	
25	215 220 225	
	ttt gaa gat gtc acc aat cct ttg cag ata atg tat agt gtg tca caa	956
	Phe Glu Asp Val Thr Asn Pro Leu Gln Ile Met Tyr Ser Val Ser Gln	
	230 235 240	
30	gga cat cga cct gtt att aat gaa gaa agt ttg cca tat gat ata cct	1004
	Gly His Arg Pro Val Ile Asn Glu Glu Ser Leu Pro Tyr Asp Ile Pro	
	245 250 255 260	
	cac cga gca cgt atg atc tct cta ata gaa agt gga tgg gca caa aat	1052
	His Arg Ala Arg Met Ile Ser Leu Ile Glu Ser Gly Trp Ala Gln Asn	
35	265 270 275	
	cca gat gaa aga cca tct ttc tta aaa tgt tta ata gaa ctt gaa cca	1100
	Pro Asp Glu Arg Pro Ser Phe Leu Lys Cys Leu Ile Glu Leu Glu Pro	
	280 285 290	
40	gtt ttg aga aca ttt gaa gag ata act ttt ctt gaa gct gtt att cag	1148
	Val Leu Arg Thr Phe Glu Glu Ile Thr Phe Leu Glu Ala Val Ile Gln	
	295 300 305	
	cta aag aaa aca aag tta cag agt gtt tca agt gcc att cac cta tgt	1196
	Leu Lys Lys Thr Lys Leu Gln Ser Val Ser Ser Ala Ile His Leu Cys	
45	310 315 320	
	gac aag aag aaa atg gaa tta tct ctg aac ata cct gta aat cat ggt	1244
	Asp Lys Lys Lys Met Glu Leu Ser Leu Asn Ile Pro Val Asn His Gly	
	325 330 335 340	
50	cca caa gag gaa tca tgt gga tcc tct cag ctc cat gaa aat agt ggt	1292
	Pro Gln Glu Glu Ser Cys Gly Ser Ser Gln Leu His Glu Asn Ser Gly	
	345 350 355	
	tct cct gaa act tca agg tcc ctg cca gct cct caa gac aat gat ttt	1340
	Ser Pro Glu Thr Ser Arg Ser Leu Pro Ala Pro Gln Asp Asn Asp Phe	
55	360 365 370	

EP 1 201 765 A2

5 tta tct aga aaa gct caa gac tgt tat ttt atg aag ctg cat cac tgt 1388
 Leu Ser Arg Lys Ala Gln Asp Cys Tyr Phe Met Lys Leu His His Cys
 375 380 385
 cct gga aat cac agt tgg gat agc acc att tct ggt tct caa agg gct 1436
 Pro Gly Asn His Ser Trp Asp Ser Thr Ile Ser Gly Ser Gln Arg Ala
 390 395 400
 10 gca ttc tgt gat cac aag acc act cca tgc tct tca gca ata ata aat 1484
 Ala Phe Cys Asp His Lys Thr Thr Pro Cys Ser Ser Ala Ile Ile Asn
 405 410 415 420
 cca ctc tca act gca gga aac tca gaa cgt ctg cag cct ggt ata gcc 1532
 Pro Leu Ser Thr Ala Gly Asn Ser Glu Arg Leu Gln Pro Gly Ile Ala
 425 430 435
 15 cag cag tgg atc cag agc aaa agg gaa gac att gtg aac caa atg aca 1580
 Gln Gln Trp Ile Gln Ser Lys Arg Glu Asp Ile Val Asn Gln Met Thr
 440 445 450
 20 gaa gcc tgc ctt aac cag tgc cta gat gcc ctt ctg tcc agg gac ttg 1628
 Glu Ala Cys Leu Asn Gln Ser Leu Asp Ala Leu Leu Ser Arg Asp Leu
 455 460 465
 atc atg aaa gag gac tat gaa ctt gtt agt acc aag cct aca agg acc 1676
 Ile Met Lys Glu Asp Tyr Glu Leu Val Ser Thr Lys Pro Thr Arg Thr
 470 475 480
 25 tca aaa gtc aga caa tta cta gac act act gac atc caa gga gaa gaa 1724
 Ser Lys Val Arg Gln Leu Leu Asp Thr Thr Asp Ile Gln Gly Glu Glu
 485 490 495 500
 30 ttt gcc aaa gtt ata gta caa aaa ttg aaa gat aac aaa caa atg ggt 1772
 Phe Ala Lys Val Ile Val Gln Lys Leu Lys Asp Asn Lys Gln Met Gly
 505 510 515
 ctt cag cct tac cag gaa ata ctt gtg gtt tct aga tca cca tct tta 1820
 Leu Gln Pro Tyr Pro Glu Ile Leu Val Val Ser Arg Ser Pro Ser Leu
 520 525 530
 35 aat tta ctt caa aat aaa agc atg taa gtgactgttt ttcaagaaga 1867
 Asn Leu Leu Gln Asn Lys Ser Met
 535 540
 40 aatgtgtttc ataaaaggat atttatatct ctgttgcttt gacttttttt atataaaatc 1927
 cgtgagtatt aaagctttat tgaaggttct ttgggtaaat attagtctcc ctccatgaca 1987
 ctgcagtatt ttttttaatt aatacaagta aaaagttgaa tttggttgaa tttgctacat 2047
 45 agttcaattt ttatgtctct tttgttaaca gaaaccactt tttaaaggata gtaattattc 2107
 ttgtttataa cagtgcctta aggtatgatg tttttctgat ggaagccatt ttcacattca 2167
 tgttcttcat ggattatttg ttacttgtct aagatgcaat ttgattttat gaagtatata 2227
 50 ccttttacct accagagaca gtacagaatc cctgccctaa aatcccaggc ttaattgccc 2287
 taaaaagggg tattaattta aaactccatt attaggatta cattttaaag ttttatttat 2347
 gaattccctt taaaaatgat atttcaaagg taaaacaata caatataaag aaaaaaataa 2407
 55 atatattaat accggcttcc tgtccccatt tttaacctca gccttcccta ctgtcaccaa 2467

EP 1 201 765 A2

caaccaagct aaataaagtc aacagcctga tgtg

2501

5
 <210> 2
 <211> 540
 <212> PRT
 <213> Homo sapiens

10
 <400> 2
 Met Asn Gly Glu Ala Ile Cys Ser Ala Leu Pro Thr Ile Pro Tyr His
 1 5 10 15
 Lys Leu Ala Asp Leu Arg Tyr Leu Ser Arg Gly Ala Ser Gly Thr Val
 20 25 30
 Ser Ser Ala Arg His Ala Asp Trp Arg Val Gln Val Ala Val Lys His
 35 40 45
 15
 Leu His Ile His Thr Pro Leu Leu Asp Ser Glu Arg Lys Asp Val Leu
 50 55 60
 Arg Glu Ala Glu Ile Leu His Lys Ala Arg Phe Ser Tyr Ile Leu Pro
 65 70 75 80
 Ile Leu Gly Ile Cys Asn Glu Pro Glu Phe Leu Gly Ile Val Thr Glu
 85 90 95
 20
 Tyr Met Pro Asn Gly Ser Leu Asn Glu Leu Leu His Arg Lys Thr Glu
 100 105 110
 Tyr Pro Asp Val Ala Trp Pro Leu Arg Phe Arg Ile Leu His Glu Ile
 115 120 125
 Ala Leu Gly Val Asn Tyr Leu His Asn Met Thr Pro Leu Leu His
 130 135 140
 25
 His Asp Leu Lys Thr Gln Asn Ile Leu Leu Asp Asn Glu Phe His Val
 145 150 155 160
 Lys Ile Ala Asp Phe Gly Leu Ser Lys Trp Arg Met Met Ser Leu Ser
 165 170 175
 Gln Ser Arg Ser Ser Lys Ser Ala Pro Glu Gly Gly Thr Ile Ile Tyr
 180 185 190
 30
 Met Pro Pro Glu Asn Tyr Glu Pro Gly Gln Lys Ser Arg Ala Ser Ile
 195 200 205
 Lys His Asp Ile Tyr Ser Tyr Ala Val Ile Thr Trp Glu Val Leu Ser
 210 215 220
 Arg Lys Gln Pro Phe Glu Asp Val Thr Asn Pro Leu Gln Ile Met Tyr
 225 230 235 240
 35
 Ser Val Ser Gln Gly His Arg Pro Val Ile Asn Glu Glu Ser Leu Pro
 245 250 255
 Tyr Asp Ile Pro His Arg Ala Arg Met Ile Ser Leu Ile Glu Ser Gly
 260 265 270
 Trp Ala Gln Asn Pro Asp Glu Arg Pro Ser Phe Leu Lys Cys Leu Ile
 275 280 285
 40
 Glu Leu Glu Pro Val Leu Arg Thr Phe Glu Glu Ile Thr Phe Leu Glu
 290 295 300
 Ala Val Ile Gln Leu Lys Lys Thr Lys Leu Gln Ser Val Ser Ser Ala
 305 310 315 320
 Ile His Leu Cys Asp Lys Lys Lys Met Glu Leu Ser Leu Asn Ile Pro
 325 330 335
 45
 Val Asn His Gly Pro Gln Glu Glu Ser Cys Gly Ser Ser Gln Leu His
 340 345 350
 Glu Asn Ser Gly Ser Pro Glu Thr Ser Arg Ser Leu Pro Ala Pro Gln
 355 360 365
 Asp Asn Asp Phe Leu Ser Arg Lys Ala Gln Asp Cys Tyr Phe Met Lys
 370 375 380
 50
 Leu His His Cys Pro Gly Asn His Ser Trp Asp Ser Thr Ile Ser Gly
 385 390 395 400
 Ser Gln Arg Ala Ala Phe Cys Asp His Lys Thr Thr Pro Cys Ser Ser
 405 410 415
 Ala Ile Ile Asn Pro Leu Ser Thr Ala Gly Asn Ser Glu Arg Leu Gln
 420 425 430
 55
 Pro Gly Ile Ala Gln Gln Trp Ile Gln Ser Lys Arg Glu Asp Ile Val

EP 1 201 765 A2

435 440 445
 Asn Gln Met Thr Glu Ala Cys Leu Asn Gln Ser Leu Asp Ala Leu Leu
 450 455 460
 5 Ser Arg Asp Leu Ile Met Lys Glu Asp Tyr Glu Leu Val Ser Thr Lys
 465 470 475 480
 Pro Thr Arg Thr Ser Lys Val Arg Gln Leu Leu Asp Thr Thr Asp Ile
 485 490 495
 Gln Gly Glu Glu Phe Ala Lys Val Ile Val Gln Lys Leu Lys Asp Asn
 500 505 510
 10 Lys Gln Met Gly Leu Gln Pro Tyr Pro Glu Ile Leu Val Val Ser Arg
 515 520 525
 Ser Pro Ser Leu Asn Leu Leu Gln Asn Lys Ser Met
 530 535 540

SEQUENCE LISTING

<110> Axxima Pharmaceuticals AG
 <120> CELLULAR KINASES INVOLVED IN CYTOMEGALOVIRUS INFECTION
 AND THEIR INHIBITION
 <130> U50062
 <140>
 <141>
 <160> 2
 <170> PatentIn Ver. 2.1
 <210> 1
 <211> 2617
 <212> DNA
 <213> Homo sapiens
 <220>
 <221> CDS
 <222> (1)..(2016)
 <400> 1
 atg caa cca gac atg tcc ttg aat gtc att aag atg aaa tcc agt gac 48
 Met Gln Pro Asp Met Ser Leu Asn Val Ile Lys Met Lys Ser Ser Asp
 1 5 10 15
 40 ttc ctg gag agt gca gaa ctg gac agc gga ggc ttt ggg aag gtg tct 96
 Phe Leu Glu Ser Ala Glu Leu Asp Ser Gly Gly Phe Gly Lys Val Ser
 20 25 30
 45 ctg tgt ttc cac aga acc cag gga ctc atg atc atg aaa aca gtg tac 144
 Leu Cys Phe His Arg Thr Gln Gly Leu Met Ile Met Lys Thr Val Tyr
 35 40 45
 aag ggg ccc aac tgc att gag cac aac gag gcc ctc ttg gag gag gcg 192
 Lys Gly Pro Asn Cys Ile Glu His Asn Glu Ala Leu Leu Glu Glu Ala
 50 55 60
 50 aag atg atg aac aga ctg aga cac agc cgg gtg gtg aag ctc ctg ggc 240
 Lys Met Met Asn Arg Leu Arg His Ser Arg Val Val Lys Leu Leu Gly
 65 70 75 80
 55 gtc atc ata gag gaa ggg aag tac tcc ctg gtg atg gag tac atg gag 288
 Val Ile Ile Glu Glu Gly Lys Tyr Ser Leu Val Met Glu Tyr Met Glu
 85 90 95

EP 1 201 765 A2

5	aag ggc aac ctg atg cac gtg ctg aaa gcc gag atg agt act ccg ctt Lys Gly Asn Leu Met His Val Leu Lys Ala Glu Met Ser Thr Pro Leu 100 105 110	336
10	tct gta aaa gga agg ata att ttg gaa atc att gaa gga atg tgc tac Ser Val Lys Gly Arg Ile Ile Leu Glu Ile Ile Glu Gly Met Cys Tyr 115 120 125	384
15	tta cat gga aaa ggc gtg ata cac aag gac ctg aag cct gaa aat atc Leu His Gly Lys Gly Val Ile His Lys Asp Leu Lys Pro Glu Asn Ile 130 135 140	432
20	ctt gtt gat aat gac ttc cac att aag atc gca gac ctc ggc ctt gcc Leu Val Asp Asn Asp Phe His Ile Lys Ile Ala Asp Leu Gly Leu Ala 145 150 155 160	480
25	tcc ttt aag atg tgg agc aaa ctg aat aat gaa gag cac aat gag ctg Ser Phe Lys Met Trp Ser Lys Leu Asn Asn Glu Glu His Asn Glu Leu 165 170 175	528
30	agg gaa gtg gac ggc acc gct aag aag aat ggc ggc acc ctc tac tac Arg Glu Val Asp Gly Thr Ala Lys Lys Asn Gly Gly Thr Leu Tyr Tyr 180 185 190	576
35	atg gcg ccc gag cac ctg aat gac gtc aac gca aag ccc aca gag aag Met Ala Pro Glu His Leu Asn Asp Val Asn Ala Lys Pro Thr Glu Lys 195 200 205	624
40	tcg gat gtg tac agc ttt gct gta gta ctc tgg gcg ata ttt gca aat Ser Asp Val Tyr Ser Phe Ala Val Val Leu Trp Ala Ile Phe Ala Asn 210 215 220	672
45	aag gag cca tat gaa aat gct atc tgt gag cag cag ttg ata atg tgc Lys Glu Pro Tyr Glu Asn Ala Ile Cys Glu Gln Gln Leu Ile Met Cys 225 230 235 240	720
50	ata aaa tct ggg aac agg cca gat gtg gat gac atc act gag tac tgc Ile Lys Ser Gly Asn Arg Pro Asp Val Asp Asp Ile Thr Glu Tyr Cys 245 250 255	768
55	cca aga gaa att atc agt ctc atg aag ctc tgc tgg gaa gcg aat ccg Pro Arg Glu Ile Ile Ser Leu Met Lys Leu Cys Trp Glu Ala Asn Pro 260 265 270	816
60	gaa gct cgg ccg aca ttt cct ggc att gaa gaa aaa ttt agg cct ttt Glu Ala Arg Pro Thr Phe Pro Gly Ile Glu Glu Lys Phe Arg Pro Phe 275 280 285	864
65	tat tta agt caa tta gaa gaa agt gta gaa gag gac gtg aag agt tta Tyr Leu Ser Gln Leu Glu Glu Ser Val Glu Glu Asp Val Lys Ser Leu 290 295 300	912
70	aag aaa gag tat tca aac gaa aat gca gtt gtg aag aga atg cag tct Lys Lys Glu Tyr Ser Asn Glu Asn Ala Val Val Lys Arg Met Gln Ser 305 310 315 320	960
75	ctt caa ctt gat tgt gtg gca gta cct tca agc cgg tca aat tca gcc Leu Gln Leu Asp Cys Val Ala Val Pro Ser Ser Arg Ser Asn Ser Ala 325 330 335	1008
80	aca gaa cag cct ggt tca ctg cac agt tcc cag gga ctt ggg atg ggt Thr Glu Gln Pro Gly Ser Leu His Ser Ser Gln Gly Leu Gly Met Gly 340 345 350	1056

EP 1 201 765 A2

5	cct gtg gag gag tcc tgg ttt gct cct tcc ctg gag cac cca caa gaa Pro Val Glu Glu Ser Trp Phe Ala Pro Ser Leu Glu His Pro Gln Glu 355 360 365	1104
	gag aat gag ccc agc ctg cag agt aaa ctc caa gac gaa gcc aac tac Glu Asn Glu Pro Ser Leu Gln Ser Lys Leu Gln Asp Glu Ala Asn Tyr 370 375 380	1152
10	cat ctt tat ggc agc cgc atg gac agg cag acg aaa cag cag ccc aga His Leu Tyr Gly Ser Arg Met Asp Arg Gln Thr Lys Gln Gln Pro Arg 385 390 395 400	1200
15	cag aat gtg gct tac aac aga gag gag gaa agg aga cgc agg gtc tcc Gln Asn Val Ala Tyr Asn Arg Glu Glu Arg Arg Arg Arg Val Ser 405 410 415	1248
	cat gac cct ttt gca cag caa aga cct tac gag aat ttt cag aat aca His Asp Pro Phe Ala Gln Gln Arg Pro Tyr Glu Asn Phe Gln Asn Thr 420 425 430	1296
20	gag gga aaa ggc act gtt tat tcc agt gca gcc agt cat ggt aat gca Glu Gly Lys Gly Thr Val Tyr Ser Ser Ala Ala Ser His Gly Asn Ala 435 440 445	1344
25	gtg cac cag ccc tca ggg ctc acc agc caa cct caa gta ctg tat cag Val His Gln Pro Ser Gly Leu Thr Ser Gln Pro Gln Val Leu Tyr Gln 450 455 460	1392
	aac aat gga tta tat agc tca cat ggc ttt gga aca aga cca ctg gat Asn Asn Gly Leu Tyr Ser Ser His Gly Phe Gly Thr Arg Pro Leu Asp 465 470 475 480	1440
30	cca gga aca gca ggt ccc aga gtt tgg tac agg cca att cca agt cat Pro Gly Thr Ala Gly Pro Arg Val Trp Tyr Arg Pro Ile Pro Ser His 485 490 495	1488
35	atg cct agt ctg cat aat atc cca gtg cct gag acc aac tat cta gga Met Pro Ser Leu His Asn Ile Pro Val Pro Glu Thr Asn Tyr Leu Gly 500 505 510	1536
	aat aca ccc acc atg cca ttc agc tcc ttg cca cca aca gat gaa tct Asn Thr Pro Thr Met Pro Phe Ser Ser Leu Pro Pro Thr Asp Glu Ser 515 520 525	1584
40	ata aaa tat acc ata tac aat agt act ggc att cag att gga gcc tac Ile Lys Tyr Thr Ile Tyr Asn Ser Thr Gly Ile Gln Ile Gly Ala Tyr 530 535 540	1632
45	aat tat atg gag att ggt ggg acg agt tca tca cta cta gac agc aca Asn Tyr Met Glu Ile Gly Gly Thr Ser Ser Ser Leu Leu Asp Ser Thr 545 550 555 560	1680
	aat acg aac ttc aaa gaa gag cca gct gct aag tac caa gct atc ttt Asn Thr Asn Phe Lys Glu Glu Pro Ala Ala Lys Tyr Gln Ala Ile Phe 565 570 575	1728
50	gat aat acc act agt ctg acg gat aaa cac ctg gac cca atc agg gaa Asp Asn Thr Thr Ser Leu Thr Asp Lys His Leu Asp Pro Ile Arg Glu 580 585 590	1776
55	aat ctg gga aag cac tgg aaa aac tgt gcc cgt aaa ctg ggc ttc aca Asn Leu Gly Lys His Trp Lys Asn Cys Ala Arg Lys Leu Gly Phe Thr 595 600 605	1824

EP 1 201 765 A2

5 cag tct cag att gat gaa att gac cat gac tat gag cga gat gga ctg 1872
 Gln Ser Gln Ile Asp Glu Ile Asp His Asp Tyr Glu Arg Asp Gly Leu
 610 615 620
 10 aaa gaa aag gtt tac cag atg ctc caa aag tgg gtg atg agg gaa ggc 1920
 Lys Glu Lys Val Tyr Gln Met Leu Gln Lys Trp Val Met Arg Glu Gly
 625 630 635 640
 15 ata aag gga gcc acg gtg ggg aag ctg gcc cag gcg ctc cac cag tgt 1968
 Ile Lys Gly Ala Thr Val Gly Lys Leu Ala Gln Ala Leu His Gln Cys
 645 650 655
 20 tcc agg atc gac ctt ctg agc agc ttg att tac gtc agc cag aac taa 2016
 Ser Arg Ile Asp Leu Leu Ser Ser Leu Ile Tyr Val Ser Gln Asn
 660 665 670
 25 ccctggatgg gctacggcag ctgaagtgga cgctcactt agcggataac ccagaaaagt 2076
 tggtgcctc agagcattca gaattctgtc ctactgata ggggttctgt gtctgcagaa 2136
 atttngtttc ctgtacttca tagctggaga atggggaaaag aaatctgcag caaaggggtc 2196
 tcaactctgtt gccaggtctgg tctcaaactt ctggactcaa gtgatectcc cgctcggcc 2256
 ttccaaagtg ctgggatatc aggcactgag ccactgcgcc cagtcaacaa tccgntctga 2316
 30 ggaaagcgta agcaggaaga cctcttaatg gcatagcacc aataaaaaaa tgactcctag 2376
 ttgtgttttg aaaggagag aagagatgtc tgaggaaggt catgttcttt cagcttatgg 2436
 catttctctag agtttngttg aagcaagaag aaaaactcag agaataataa atcaactttt 2496
 35 aaaattgtgt gctctcttct tcacgtaggc tcctgttaaa aacaaagtgc agtcagattc 2556
 taagccctgt tcagagactt cgcggatcac agctgcagct caccgccaca tcacaggatc 2616
 c - 2617
 <210> 2
 <211> 671
 <212> PRT
 <213> Homo sapiens
 <400> 2
 40 Met Gln Pro Asp Met Ser Leu Asn Val Ile Lys Met Lys Ser Ser Asp
 1 5 10 15
 Phe Leu Glu Ser Ala Glu Leu Asp Ser Gly Gly Phe Gly Lys Val Ser
 20 25 30
 Leu Cys Phe His Arg Thr Gln Gly Leu Met Ile Met Lys Thr Val Tyr
 35 40 45
 45 Lys Gly Pro Asn Cys Ile Glu His Asn Glu Ala Leu Leu Glu Glu Ala
 50 55 60
 Lys Met Met Asn Arg Leu Arg His Ser Arg Val Val Lys Leu Leu Gly
 65 70 75 80
 Val Ile Ile Glu Glu Gly Lys Tyr Ser Leu Val Met Glu Tyr Met Glu
 85 90 95
 50 Lys Gly Asn Leu Met His Val Leu Lys Ala Glu Met Ser Thr Pro Leu
 100 105 110
 Ser Val Lys Gly Arg Ile Ile Leu Glu Ile Ile Glu Gly Met Cys Tyr
 115 120 125
 Leu His Gly Lys Gly Val Ile His Lys Asp Leu Lys Pro Glu Asn Ile
 130 135 140
 55 Leu Val Asp Asn Asp Phe His Ile Lys Ile Ala Asp Leu Gly Leu Ala
 145 150 155 160

EP 1 201 765 A2

	Ser	Phe	Lys	Met	Trp	Ser	Lys	Leu	Asn	Asn	Glu	Glu	His	Asn	Glu	Leu
				165						170					175	
5	Arg	Glu	Val	Asp	Gly	Thr	Ala	Lys	Lys	Asn	Gly	Gly	Thr	Leu	Tyr	Tyr
				180					185					190		
	Met	Ala	Pro	Glu	His	Leu	Asn	Asp	Val	Asn	Ala	Lys	Pro	Thr	Glu	Lys
			195					200					205			
	Ser	Asp	Val	Tyr	Ser	Phe	Ala	Val	Val	Leu	Trp	Ala	Ile	Phe	Ala	Asn
		210				215						220				
10	Lys	Glu	Pro	Tyr	Glu	Asn	Ala	Ile	Cys	Glu	Gln	Gln	Leu	Ile	Met	Cys
	225					230					235				240	
	Ile	Lys	Ser	Gly	Asn	Arg	Pro	Asp	Val	Asp	Asp	Ile	Thr	Glu	Tyr	Cys
				245					250					255		
	Pro	Arg	Glu	Ile	Ile	Ser	Leu	Met	Lys	Leu	Cys	Trp	Glu	Ala	Asn	Pro
			260						265					270		
15	Glu	Ala	Arg	Pro	Thr	Phe	Pro	Gly	Ile	Glu	Glu	Lys	Phe	Arg	Pro	Phe
			275				280						285			
	Tyr	Leu	Ser	Gln	Leu	Glu	Glu	Ser	Val	Glu	Glu	Asp	Val	Lys	Ser	Leu
		290				295						300				
	Lys	Lys	Glu	Tyr	Ser	Asn	Glu	Asn	Ala	Val	Val	Lys	Arg	Met	Gln	Ser
	305					310					315				320	
20	Leu	Gln	Leu	Asp	Cys	Val	Ala	Val	Pro	Ser	Ser	Arg	Ser	Asn	Ser	Ala
				325					330						335	
	Thr	Glu	Gln	Pro	Gly	Ser	Leu	His	Ser	Ser	Gln	Gly	Leu	Gly	Met	Gly
			340						345					350		
	Pro	Val	Glu	Glu	Ser	Trp	Phe	Ala	Pro	Ser	Leu	Glu	His	Pro	Gln	Glu
			355				360						365			
25	Glu	Asn	Glu	Pro	Ser	Leu	Gln	Ser	Lys	Leu	Gln	Asp	Glu	Ala	Asn	Tyr
		370				375						380				
	His	Leu	Tyr	Gly	Ser	Arg	Met	Asp	Arg	Gln	Thr	Lys	Gln	Gln	Pro	Arg
		385				390					395				400	
	Gln	Asn	Val	Ala	Tyr	Asn	Arg	Glu	Glu	Glu	Arg	Arg	Arg	Arg	Val	Ser
			405						410					415		
30	His	Asp	Pro	Phe	Ala	Gln	Gln	Arg	Pro	Tyr	Glu	Asn	Phe	Gln	Asn	Thr
			420						425					430		
	Glu	Gly	Lys	Gly	Thr	Val	Tyr	Ser	Ser	Ala	Ala	Ser	His	Gly	Asn	Ala
			435					440					445			
	Val	His	Gln	Pro	Ser	Gly	Leu	Thr	Ser	Gln	Pro	Gln	Val	Leu	Tyr	Gln
		450				455						460				
35	Asn	Asn	Gly	Leu	Tyr	Ser	Ser	His	Gly	Phe	Gly	Thr	Arg	Pro	Leu	Asp
		465				470					475				480	
	Pro	Gly	Thr	Ala	Gly	Pro	Arg	Val	Trp	Tyr	Arg	Pro	Ile	Pro	Ser	His
			485						490					495		
	Met	Pro	Ser	Leu	His	Asn	Ile	Pro	Val	Pro	Glu	Thr	Asn	Tyr	Leu	Gly
			500						505					510		
40	Asn	Thr	Pro	Thr	Met	Pro	Phe	Ser	Ser	Leu	Pro	Pro	Thr	Asp	Glu	Ser
			515					520					525			
	Ile	Lys	Tyr	Thr	Ile	Tyr	Asn	Ser	Thr	Gly	Ile	Gln	Ile	Gly	Ala	Tyr
		530				535						540				
	Asn	Tyr	Met	Glu	Ile	Gly	Gly	Thr	Ser	Ser	Ser	Leu	Leu	Asp	Ser	Thr
		545				550					555				560	
45	Asn	Thr	Asn	Phe	Lys	Glu	Glu	Pro	Ala	Ala	Lys	Tyr	Gln	Ala	Ile	Phe
			565						570					575		
	Asp	Asn	Thr	Thr	Ser	Leu	Thr	Asp	Lys	His	Leu	Asp	Pro	Ile	Arg	Glu
			580						585					590		
	Asn	Leu	Gly	Lys	His	Trp	Lys	Asn	Cys	Ala	Arg	Lys	Leu	Gly	Phe	Thr
		595					600						605			
50	Gln	Ser	Gln	Ile	Asp	Glu	Ile	Asp	His	Asp	Tyr	Glu	Arg	Asp	Gly	Leu
		610				615						620				
	Lys	Glu	Lys	Val	Tyr	Gln	Met	Leu	Gln	Lys	Trp	Val	Met	Arg	Glu	Gly
		625				630					635				640	
	Ile	Lys	Gly	Ala	Thr	Val	Gly	Lys	Leu	Ala	Gln	Ala	Leu	His	Gln	Cys
			645						650					655		
55	Ser	Arg	Ile	Asp	Leu	Leu	Ser	Ser	Leu	Ile	Tyr	Val	Ser	Gln	Asn	
			660						665					670		

EP 1 201 765 A2

SEQUENCE LISTING

5 <110> Axxima Pharmaceuticals AG

<120> CELLULAR KINASES INVOLVED IN CYTOMEGALOVIRUS INFECTION
AND THEIR INHIBITION

10 <130> Y10256

<140>

<141>

<160> 2

15 <170> PatentIn Ver. 2.1

<210> 1

<211> 4596

<212> DNA

20 <213> Homo sapiens

<220>

<221> CDS

<222> (233)..(3076)

25 <400> 1

aagcggggga ctgtgccgtg tggaacgtgt agctgttgag aggtggactc tgttaccatt 60

gaggatgttt ggaggatgag tatgtgtggc agaggcacac ataaacaggc agagaccctt 120

tgccctgcc ttctctcccc aacccaaggc tgacctgtgt tctcccaggt ctgggattct 180

30 aagtgcctg ctctgtgttt ggtctctctc aggatgagca caagcctggg ag atg gca 238

Met Ala

1

gtg atg gaa atg gcc tgc cca ggt gcc cct ggc tca gca gtg ggg cag 286

35 Val Met Glu Met Ala Cys Pro Gly Ala Pro Gly Ser Ala Val Gly Gln

5 10 15

cag aag gaa ctc ccc aag cca aag gag aag acg ccg cca ctg ggg aag 334

Gln Lys Glu Leu Pro Lys Pro Lys Glu Lys Thr Pro Pro Leu Gly Lys

20 25 30

40 aaa cag agc tcc gtc tac aag ctt gag gcc gtg gag aag agc cct gtg 382

Lys Gln Ser Ser Val Tyr Lys Leu Glu Ala Val Glu Lys Ser Pro Val

35 40 45 50

45 ttc tgc gga aag tgg gag atc ctg aat gac gtg att acc aag ggc aca 430

Phe Cys Gly Lys Trp Glu Ile Leu Asn Asp Val Ile Thr Lys Gly Thr

55 60 65

gcc aag gaa ggc tcc gag gca ggg cca gct gcc atc tct atc atc gcc 478

Ala Lys Glu Gly Ser Glu Ala Gly Pro Ala Ala Ile Ser Ile Ile Ala

70 75 80

50 cag gct gag tgt gag aat agc caa gag ttc agc ccc acc ttt tca gaa 526

Gln Ala Glu Cys Glu Asn Ser Gln Glu Phe Ser Pro Thr Phe Ser Glu

85 90 95

55 cgc att ttc atc gct ggg tcc aaa cag tac agc cag tcc gag agt ctt 574

Arg Ile Phe Ile Ala Gly Ser Lys Gln Tyr Ser Gln Ser Glu Ser Leu

100 105 110

EP 1 201 765 A2

5	gat cag atc ccc aac aat gtg gcc cat gct aca gag ggc aaa atg gcc Asp Gln Ile Pro Asn Asn Val Ala His Ala Thr Glu Gly Lys Met Ala 115 120 125 130	622
	cgt gtg tgt tgg aag gga aag cgt cgc agc aaa gcc cgg aag aaa cgg Arg Val Cys Trp Lys Gly Lys Arg Arg Ser Lys Ala Arg Lys Lys Arg 135 140 145	670
10	aag aag aag agc tca aag tcc ctg gct cat gca gga gtg gcc ttg gcc Lys Lys Lys Ser Ser Lys Ser Leu Ala His Ala Gly Val Ala Leu Ala 150 155 160	718
15	aaa ccc ctc ccc agg acc cct gag cag gag agc tgc acc atc cca gtg Lys Pro Leu Pro Arg Thr Pro Glu Gln Glu Ser Cys Thr Ile Pro Val 165 170 175	766
	cag gag gat gag tct cca ctc ggc gcc cca tat gtt aga aac acc ccg Gln Glu Asp Glu Ser Pro Leu Gly Ala Pro Tyr Val Arg Asn Thr Pro 180 185 190	814
20	cag ttc acc aag cct ctg aag gaa cca ggc ctt ggg caa ctc tgt ttt Gln Phe Thr Lys Pro Leu Lys Glu Pro Gly Leu Gly Gln Leu Cys Phe 195 200 205 210	862
25	aag cag ctt ggc gag ggc cta cgg ccg gct ctg cct cga tca gaa ctc Lys Gln Leu Gly Glu Gly Leu Arg Pro Ala Leu Pro Arg Ser Glu Leu 215 220 225	910
	cac aaa ctg atc agc ccc ttg caa tgt ctg aac cac gtg tgg aaa ctg His Lys Leu Ile Ser Pro Leu Gln Cys Leu Asn His Val Trp Lys Leu 230 235 240	958
30	cac cac ccc cag gac gga ggc ccc ctg ccc ctg ccc acg cac ccc ttc His His Pro Gln Asp Gly Gly Pro Leu Pro Leu Pro Thr His Pro Phe 245 250 255	1006
35	ccc tat agc aga ctg cct cat ccc ttc cca ttc cac cct ctc cag ccc Pro Tyr Ser Arg Leu Pro His Pro Phe Pro Phe His Pro Leu Gln Pro 260 265 270	1054
	tgg aaa cct cac cct ctg gag tcc ttc ctg ggc aaa ctg gcc tgt gta Trp Lys Pro His Pro Leu Glu Ser Phe Leu Gly Lys Leu Ala Cys Val 275 280 285 290	1102
40	gac agc cag aaa ccc ttg cct gac cca cac ctg agc aaa ctg gcc tgt Asp Ser Gln Lys Pro Leu Pro Asp Pro His Leu Ser Lys Leu Ala Cys 295 300 305	1150
45	gta gac agt cca aag ccc ctg cct ggc cca cac ctg gag ccc agc tgc Val Asp Ser Pro Lys Pro Leu Pro Gly Pro His Leu Glu Pro Ser Cys 310 315 320	1198
	ctg tct cgt ggt gcc cat gag aag ttt tct gtg gag gaa tac cta gtg Leu Ser Arg Gly Ala His Glu Lys Phe Ser Val Glu Glu Tyr Leu Val 325 330 335	1246
50	cat gct ctg caa ggc agc gtg agc tca agc cag gcc cac agc ctg acc His Ala Leu Gln Gly Ser Val Ser Ser Ser Gln Ala His Ser Leu Thr 340 345 350	1294
55	agc ctg gcc aag acc tgg gca gca cgg ggc tcc aga tcc cgg gag ccc Ser Leu Ala Lys Thr Trp Ala Ala Arg Gly Ser Arg Ser Arg Glu Pro 355 360 365 370	1342

EP 1 201 765 A2

5	agc ccc aaa act gag gac aac gag ggt gtc ctg ctc act gag aaa ctc Ser Pro Lys Thr Glu Asp Asn Glu Gly Val Leu Leu Thr Glu Lys Leu 375 380 385	1390
10	aag cca gtg gat tat gag tac cga gaa gaa gtc cac tgg gcc acg cac Lys Pro Val Asp Tyr Glu Tyr Arg Glu Glu Val His Trp Ala Thr His 390 395 400	1438
15	cag ctc cgc ctg ggc aga ggc tcc ttc gga gag gtg cac agg atg gag Gln Leu Arg Leu Gly Arg Gly Ser Phe Gly Glu Val His Arg Met Glu 405 410 415	1486
20	gac aag cag act ggc ttc cag tgc gct gtc aaa aag gtg cgg ctg gaa Asp Lys Gln Thr Gly Phe Gln Cys Ala Val Lys Lys Val Arg Leu Glu 420 425 430	1534
25	gta ttt cgg gca gag gag ctg atg gca tgt gca gga ttg acc tca ccc Val Phe Arg Ala Glu Glu Leu Met Ala Cys Ala Gly Leu Thr Ser Pro 435 440 445 450	1582
30	aga att gtc cct ttg tat gga gct gtg aga gaa ggg cct tgg gtc aac Arg Ile Val Pro Leu Tyr Gly Ala Val Arg Glu Gly Pro Trp Val Asn 455 460 465	1630
35	atc ttc atg gag ctg ctg gaa ggt ggc tcc ctg ggc cag ctg gtc aag Ile Phe Met Glu Leu Leu Glu Gly Ser Leu Gly Gln Leu Val Lys 470 475 480	1678
40	gag cag ggc tgt ctc cca gag gac cgg gcc ctg tac tac ctg ggc cag Glu Gln Gly Cys Leu Pro Glu Asp Arg Ala Leu Tyr Tyr Leu Gly Gln 485 490 495	1726
45	gcc ctg gag ggt ctg gaa tac ctc cac tca cga agg att ctg cat ggg Ala Leu Glu Gly Leu Glu Tyr Leu His Ser Arg Arg Ile Leu His Gly 500 505 510	1774
50	gac gtc aaa gct gac aac gtg ctc ctg tcc agc gat ggg agc cac gca Asp Val Lys Ala Asp Asn Val Leu Leu Ser Ser Asp Gly Ser His Ala 515 520 525 530	1822
55	gcc ctc tgt gac ttt ggc cat gct gtg tgt ctt caa cct gat ggc ctg Ala Leu Cys Asp Phe Gly His Ala Val Cys Leu Gln Pro Asp Gly Leu 535 540 545	1870
60	gga aag tcc ttg ctc aca ggg gac tac atc cct ggc aca gag acc cac Gly Lys Ser Leu Leu Thr Gly Asp Tyr Ile Pro Gly Thr Glu Thr His 550 555 560	1918
65	atg gct ccg gag gtg gtg ctg ggc agg agc tgc gac gcc aag gtg gat Met Ala Pro Glu Val Val Leu Gly Arg Ser Cys Asp Ala Lys Val Asp 565 570 575	1966
70	gtc tgg agc agc tgc tgt atg atg ctg cac atg ctc aac ggc tgc cac Val Trp Ser Ser Cys Cys Met Met Leu His Met Leu Asn Gly Cys His 580 585 590	2014
75	ccc tgg act cag ttc ttc cga ggg ccg ctc tgc ctc aag att gcc agc Pro Trp Thr Gln Phe Phe Arg Gly Pro Leu Cys Leu Lys Ile Ala Ser 595 600 605 610	2062
80	gag cct ccg cct gtg agg gag atc cca ccc tcc tgc gcc cct ctc aca Glu Pro Pro Pro Val Arg Glu Ile Pro Pro Ser Cys Ala Pro Leu Thr 615 620 625	2110

EP 1 201 765 A2

5	gcc cag gcc atc caa gag ggg ctg agg aaa gag ccc atc cac cgc gtg Ala Gln Ala Ile Gln Glu Gly Leu Arg Lys Glu Pro Ile His Arg Val 630 635 640	2158
	tct gca gcg gag ctg gga ggg aag gtg aac cgg gca cta cag caa gtg Ser Ala Ala Glu Leu Gly Gly Lys Val Asn Arg Ala Leu Gln Gln Val 645 650 655	2206
10	gga ggt ctg aag agc cct tgg agg gga gaa tat aaa gaa cca aga cat Gly Gly Leu Lys Ser Pro Trp Arg Gly Glu Tyr Lys Glu Pro Arg His 660 665 670	2254
15	cca ccg cca aat caa gcc aat tac cac cag acc ctc cat gcc cag ccg Pro Pro Pro Asn Gln Ala Asn Tyr His Gln Thr Leu His Ala Gln Pro 675 680 685 690	2302
	aga gag ctt tcg cca agg gcc cca ggg ccc cgg cca gct gag gag aca Arg Glu Leu Ser Pro Arg Ala Pro Gly Pro Arg Pro Ala Glu Glu Thr 695 700 705	2350
20	aca ggc aga gcc cct aag ctc cag cct ctc cca cca gag ccc cca Thr Gly Arg Ala Pro Lys Leu Gln Pro Pro Leu Pro Pro Glu Pro Pro 710 715 720	2398
25	gag cca aac aag tct cct ccc ttg act ttg agc aag gag gag tct ggg Glu Pro Asn Lys Ser Pro Pro Thr Leu Ser Lys Glu Glu Ser Gly 725 730 735	2446
	atg tgg gaa ccc tta cct ctg tcc tcc ctg gag cca gcc cct gcc aga Met Trp Glu Pro Leu Pro Ser Ser Ser Leu Glu Pro Ala Pro Ala Arg 740 745 750	2494
30	aac ccc agc tca cca gag cgg aaa gca acc gtc ccg gag cag gaa ctg Asn Pro Ser Ser Pro Arg Lys Ala Thr Val Pro Glu Gln Glu Leu 755 760 765 770	2542
35	cag cag ctg gaa ata gaa tta ttc ctc aac agc ctg tcc cag cca ttt Gln Gln Leu Glu Ile Glu Leu Phe Leu Asn Ser Leu Ser Gln Pro Phe 775 780 785	2590
	tct ctg gag gag cag gag caa att ctc tcg tgc ctc agc atc gac agc Ser Leu Glu Glu Gln Glu Gln Ile Leu Ser Cys Leu Ser Ile Asp Ser 790 795 800	2638
40	ctc tcc ctg tcg gat gac agt gag aag aac cca tca aag gcc tct caa Leu Ser Leu Ser Asp Asp Ser Glu Lys Asn Pro Ser Lys Ala Ser Gln 805 810 815	2686
45	agc tcg cgg gac acc ctg agc tca ggc gta cac tcc tgg agc agc cag Ser Ser Arg Asp Thr Leu Ser Ser Gly Val His Ser Trp Ser Ser Gln 820 825 830	2734
	gcc gag gct cga agc tcc agc tgg aac atg gtg ctg gcc cgg ggg cgg Ala Glu Ala Arg Ser Ser Ser Trp Asn Met Val Leu Ala Arg Gly Arg 835 840 845 850	2782
50	ccc acc gac acc cca agc tat ttc aat ggt gtg aaa gtc caa ata cag Pro Thr Asp Thr Pro Ser Tyr Phe Asn Gly Val Lys Val Gln Ile Gln 855 860 865	2830
55	tct ctt aat ggt gaa cac ctg cac atc cgg gag ttc cac cgg gtc aaa Ser Leu Asn Gly Glu His Leu His Ile Arg Glu Phe His Arg Val Lys 870 875 880	2878

EP 1 201 765 A2

5 gtg gga gac atc gcc act ggc atc agc agc cag atc cca gct gca gcc 2926
 Val Gly Asp Ile Ala Thr Gly Ile Ser Ser Gln Ile Pro Ala Ala Ala
 885 890 895

 ttc agc ttg gtc acc aaa gac ggg cag cct gtt cgc tac gac atg gag 2974
 Phe Ser Leu Val Thr Lys Asp Gly Gln Pro Val Arg Tyr Asp Met Glu
 900 905 910

 10 gtg cca gac tgc ggc atc gac ctg cag tgc aca ctg gcc cct gat ggc 3022
 Val Pro Asp Ser Gly Ile Asp Leu Gln Cys Thr Leu Ala Pro Asp Gly
 915 920 925 930

 agc ttc gcc tgg agc tgg agg gtc aag cat ggc cag ctg gag aac agg 3070
 Ser Phe Ala Trp Ser Trp Arg Val Lys His Gly Gln Leu Glu Asn Arg
 935 940 945

 ccc taa ccttgccttc caccgcgcgc tccacactgc cggaaagcag ccttctctgct 3126
 Pro

 20 cgggtgcacga tgcctgcctg aaaacacagg ctccagccgtt cccaggggat tgccagcccc 3186
 ccggctcaca gtgggaacca gggcctcgca gcagcaagggt gggggcaagc agaatgcctc 3246
 ccaggatttc acacctgagc cctgccccac cctgctgaaa aaacatccgc cacgtgaaga 3306

 25 gacagaagga ggatggcagg agttacctgg ggaacaaaaa cagggatctt tttctgcccc 3366
 tgctccagtc gagttggcct gacccgcttg gatcagtgac catttggttg cagacagggg 3426
 agagcagctt ccagcctggg tcagaagggg tgggcgagcc cttcggcccc tcaccctcca 3486

 30 ggctgctgtg agagtgtcaa gtgtgtaagg gcccaaaactc aggttcagtg cagaaccagg 3546
 tcagcaggta tgcccgcccc taggttaagg gggccctcta aaccctctgc ctggcctcac 3606
 ctggccagct caccctttt ggggtgtagg gaaaagaatg cctgaccctg ggaaggctcc 3666

 35 ctggtagaat acaccacact tttcagggtg ttgcaacaca ggtcctgagt tgacctctgg 3726
 ttcagccaag gaccaaagaa ggtgtgtaag tgaagtgggt ctccagtcctc agacatgtgc 3786
 ccctttgctg ctggctacca ctcttcccca gagcagcagg ccccgagccc ctccaggccc 3846

 40 agcactgccc cagactcgct ggcactcagt tccctcatct gtaaagggtga aggggtgatgc 3906
 aggatatgcc tgacaggaac agtctgtgga tggacatgat cagtgcctaag gaaagcagca 3966
 gagagagacg tccggcgccc cagccccact atcagtgtcc agcgtgctgg tccccagag 4026

 45 cacagctcag catcactctg aactcacc tcacctgccc ctggccagag ggtactgccg 4086
 acggcacttt gcaactctgat gacctcaaag cactttcatg gctgcccctc ggcagggcag 4146
 ggcagggcag tgacactgta ggagcatagc aagccaggag atgggggtgaa gggacacagt 4206

 50 cttgagctgt ccacatgcat gtgactcctc aaacctcttc cagatttctc taagaatagc 4266
 accccttcc ccattgcccc agcttagcct ctctctccag gggagctact caggactcac 4326
 gtagcattaa atcagctgtg aatcgtcagg ggggtgtctg tagcctcaac ctctgggggc 4386

 55 aggggacgcc gagactcctg gggagaagct cattcccaca tcttgccaag acagcctttg 4446

EP 1 201 765 A2

5 tccagctgtc cacattgagt cagactgttc ccggggagag agccccggcc cccagcacat 4506
 aaagaactgc agccttggtg ctgcagagtc tgggtttagt agaactcttt gtaagcaata 4566
 aagtttgggg tgatgacaaa tgttaaaaaa 4596

10 <210> 2
 <211> 947
 <212> PRT
 <213> Homo sapiens

<400> 2
 15 Met Ala Val Met Glu Met Ala Cys Pro Gly Ala Pro Gly Ser Ala Val
 1 5 10 15
 Gly Gln Gln Lys Glu Leu Pro Lys Pro Lys Glu Lys Thr Pro Pro Leu
 20 25 30
 Gly Lys Lys Gln Ser Ser Val Tyr Lys Leu Glu Ala Val Glu Lys Ser
 35 40 45
 Pro Val Phe Cys Gly Lys Trp Glu Ile Leu Asn Asp Val Ile Thr Lys
 50 55 60
 20 Gly Thr Ala Lys Glu Gly Ser Glu Ala Gly Pro Ala Ala Ile Ser Ile
 65 70 75 80
 Ile Ala Gln Ala Glu Cys Glu Asn Ser Gln Glu Phe Ser Pro Thr Phe
 85 90 95
 25 Ser Glu Arg Ile Phe Ile Ala Gly Ser Lys Gln Tyr Ser Gln Ser Glu
 100 105 110
 Ser Leu Asp Gln Ile Pro Asn Asn Val Ala His Ala Thr Glu Gly Lys
 115 120 125
 Met Ala Arg Val Cys Trp Lys Gly Lys Arg Arg Ser Lys Ala Arg Lys
 130 135 140
 30 Lys Arg Lys Lys Lys Ser Ser Lys Ser Leu Ala His Ala Gly Val Ala
 145 150 155 160
 Leu Ala Lys Pro Leu Pro Arg Thr Pro Glu Gln Glu Ser Cys Thr Ile
 165 170 175
 Pro Val Gln Glu Asp Glu Ser Pro Leu Gly Ala Pro Tyr Val Arg Asn
 180 185 190
 35 Thr Pro Gln Phe Thr Lys Pro Leu Lys Glu Pro Gly Leu Gly Gln Leu
 195 200 205
 Cys Phe Lys Gln Leu Gly Glu Gly Leu Arg Pro Ala Leu Pro Arg Ser
 210 215 220
 Glu Leu His Lys Leu Ile Ser Pro Leu Gln Cys Leu Asn His Val Trp
 225 230 235 240
 40 Lys Leu His His Pro Gln Asp Gly Gly Pro Leu Pro Leu Pro Thr His
 245 250 255
 Pro Phe Pro Tyr Ser Arg Leu Pro His Pro Phe Pro Phe His Pro Leu
 260 265 270
 Gln Pro Trp Lys Pro His Pro Leu Glu Ser Phe Leu Gly Lys Leu Ala
 275 280 285
 45 Cys Val Asp Ser Gln Lys Pro Leu Pro Asp Pro His Leu Ser Lys Leu
 290 295 300
 Ala Cys Val Asp Ser Pro Lys Pro Leu Pro Gly Pro His Leu Glu Pro
 305 310 315 320
 Ser Cys Leu Ser Arg Gly Ala His Glu Lys Phe Ser Val Glu Glu Tyr
 325 330 335
 50 Leu Val His Ala Leu Gln Gly Ser Val Ser Ser Ser Gln Ala His Ser
 340 345 350
 Leu Thr Ser Leu Ala Lys Thr Trp Ala Ala Arg Gly Ser Arg Ser Arg
 355 360 365
 Glu Pro Ser Pro Lys Thr Glu Asp Asn Glu Gly Val Leu Leu Thr Glu
 370 375 380
 55 Lys Leu Lys Pro Val Asp Tyr Glu Tyr Arg Glu Glu Val His Trp Ala
 385 390 395 400
 Thr His Gln Leu Arg Leu Gly Arg Gly Ser Phe Gly Glu Val His Arg

EP 1 201 765 A2

				405					410				415			
	Met	Glu	Asp	Lys	Gln	Thr	Gly	Phe	Gln	Cys	Ala	Val	Lys	Lys	Val	Arg
5				420					425				430			
	Leu	Glu	Val	Phe	Arg	Ala	Glu	Glu	Leu	Met	Ala	Cys	Ala	Gly	Leu	Thr
				435					440				445			
	Ser	Pro	Arg	Ile	Val	Pro	Leu	Tyr	Gly	Ala	Val	Arg	Glu	Gly	Pro	Trp
				450					455				460			
	Val	Asn	Ile	Phe	Met	Glu	Leu	Leu	Glu	Gly	Gly	Ser	Leu	Gly	Gln	Leu
10	465					470					475				480	
	Val	Lys	Glu	Gln	Gly	Cys	Leu	Pro	Glu	Asp	Arg	Ala	Leu	Tyr	Tyr	Leu
					485					490					495	
	Gly	Gln	Ala	Leu	Glu	Gly	Leu	Glu	Tyr	Leu	His	Ser	Arg	Arg	Ile	Leu
				500					505					510		
	His	Gly	Asp	Val	Lys	Ala	Asp	Asn	Val	Leu	Leu	Ser	Ser	Asp	Gly	Ser
15				515				520					525			
	His	Ala	Ala	Leu	Cys	Asp	Phe	Gly	His	Ala	Val	Cys	Leu	Gln	Pro	Asp
				530				535					540			
	Gly	Leu	Gly	Lys	Ser	Leu	Leu	Thr	Gly	Asp	Tyr	Ile	Pro	Gly	Thr	Glu
	545					550					555				560	
	Thr	His	Met	Ala	Pro	Glu	Val	Val	Leu	Gly	Arg	Ser	Cys	Asp	Ala	Lys
20					565					570					575	
	Val	Asp	Val	Trp	Ser	Ser	Cys	Cys	Met	Met	Leu	His	Met	Leu	Asn	Gly
				580					585					590		
	Cys	His	Pro	Trp	Thr	Gln	Phe	Phe	Arg	Gly	Pro	Leu	Cys	Leu	Lys	Ile
				595				600					605			
	Ala	Ser	Glu	Pro	Pro	Pro	Val	Arg	Glu	Ile	Pro	Pro	Ser	Cys	Ala	Pro
25				610				615					620			
	Leu	Thr	Ala	Gln	Ala	Ile	Gln	Glu	Gly	Leu	Arg	Lys	Glu	Pro	Ile	His
	625					630					635				640	
	Arg	Val	Ser	Ala	Ala	Glu	Leu	Gly	Gly	Lys	Val	Asn	Arg	Ala	Leu	Gln
					645					650					655	
	Gln	Val	Gly	Gly	Leu	Lys	Ser	Pro	Trp	Arg	Gly	Glu	Tyr	Lys	Glu	Pro
30				660					665					670		
	Arg	His	Pro	Pro	Pro	Asn	Gln	Ala	Asn	Tyr	His	Gln	Thr	Leu	His	Ala
				675				680					685			
	Gln	Pro	Arg	Glu	Leu	Ser	Pro	Arg	Ala	Pro	Gly	Pro	Arg	Pro	Ala	Glu
				690				695					700			
	Glu	Thr	Thr	Gly	Arg	Ala	Pro	Lys	Leu	Gln	Pro	Pro	Leu	Pro	Pro	Glu
35	705					710					715				720	
	Pro	Pro	Glu	Pro	Asn	Lys	Ser	Pro	Pro	Leu	Thr	Leu	Ser	Lys	Glu	Glu
					725					730					735	
	Ser	Gly	Met	Trp	Glu	Pro	Leu	Pro	Leu	Ser	Ser	Leu	Glu	Pro	Ala	Pro
				740					745					750		
	Ala	Arg	Asn	Pro	Ser	Ser	Pro	Glu	Arg	Lys	Ala	Thr	Val	Pro	Glu	Gln
40				755				760					765			
	Glu	Leu	Gln	Gln	Leu	Glu	Ile	Glu	Leu	Phe	Leu	Asn	Ser	Leu	Ser	Gln
				770				775				780				
	Pro	Phe	Ser	Leu	Glu	Glu	Gln	Glu	Gln	Ile	Leu	Ser	Cys	Leu	Ser	Ile
	785					790					795				800	
	Asp	Ser	Leu	Ser	Leu	Ser	Asp	Asp	Ser	Glu	Lys	Asn	Pro	Ser	Lys	Ala
45					805					810					815	
	Ser	Gln	Ser	Ser	Arg	Asp	Thr	Leu	Ser	Ser	Gly	Val	His	Ser	Trp	Ser
				820					825					830		
	Ser	Gln	Ala	Glu	Ala	Arg	Ser	Ser	Ser	Trp	Asn	Met	Val	Leu	Ala	Arg
				835				840					845			
	Gly	Arg	Pro	Thr	Asp	Thr	Pro	Ser	Tyr	Phe	Asn	Gly	Val	Lys	Val	Gln
50				850				855					860			
	Ile	Gln	Ser	Leu	Asn	Gly	Glu	His	Leu	His	Ile	Arg	Glu	Phe	His	Arg
	865					870					875				880	
	Val	Lys	Val	Gly	Asp	Ile	Ala	Thr	Gly	Ile	Ser	Ser	Gln	Ile	Pro	Ala
					885					890					895	
	Ala	Ala	Phe	Ser	Leu	Val	Thr	Lys	Asp	Gly	Gln	Pro	Val	Arg	Tyr	Asp
55				900					905					910		
	Met	Glu	Val	Pro	Asp	Ser	Gly	Ile	Asp	Leu	Gln	Cys	Thr	Leu	Ala	Pro

EP 1 201 765 A2

915 920 925
 Asp Gly Ser Phe Ala Trp Ser Trp Arg Val Lys His Gly Gln Leu Glu
 930 935 940
 Asn Arg Pro
 945

SEQUENCE LISTING

<110> Axxima Pharmaceuticals AG
 <120> CELLULAR KINASES INVOLVED IN CYTOMEGALOVIRUS INFECTION
 AND THEIR INHIBITION
 <130> NM002756
 <140>
 <141>
 <160> 2
 <170> PatentIn Ver. 2.1
 <210> 1
 <211> 2030
 <212> DNA
 <213> Homo sapiens
 <220>
 <221> CDS
 <222> (338) .. (1294)
 <400> 1
 tggctggcaa tggccttgct gacctcgagc cgggcccacg tggggacctt tggagcacag 60
 cctacgatcc tgggtgcaagg cgggtggatg cagaggccag tccatatacc acccaggcct 120
 gcgaggagcg tgggtcccccac ccatccagcc catatgtgca agtgcccttg acagagagggc 180
 tgggtcatatc catggtgacc atttatgggc cacaacaggt ccccatctgc gcagtgaacc 240
 ctgtgctgag caccttgacg acgtgatctt gcttcgtcct gcagcactgt gcggggcagg 300
 aaaatccaag aggaagaagg atctacggat atcctgc atg tcc aag cca ccc gca 355
 Met Ser Lys Pro Pro Ala
 1 5
 ccc aac ccc aca ccc ccc cgg aac ctg gac tcc cgg acc ttc atc acc 403
 Pro Asn Pro Thr Pro Pro Arg Asn Leu Asp Ser Arg Thr Phe Ile Thr
 10 15 20
 att gga gac aga aac ttt gag gtg gag gct gat gac ttg gtg acc atc 451
 Ile Gly Asp Arg Asn Phe Glu Val Glu Ala Asp Asp Leu Val Thr Ile
 25 30 35
 tca gaa ctg ggc cgt gga gcc tat ggg gtg gta gag aag gtg cgg cac 499
 Ser Glu Leu Gly Arg Gly Ala Tyr Gly Val Val Glu Lys Val Arg His
 40 45 50
 gcc cag agc ggc acc atc atg gcc gtg aag cgg atc cgg gcc acc gtg 547
 Ala Gln Ser Gly Thr Ile Met Ala Val Lys Arg Ile Arg Ala Thr Val
 55 60 65 70

EP 1 201 765 A2

5	aac tca cag gag cag aag cgg ctg ctc atg gac ctg gac atc aac atg Asn Ser Gln Glu Gln Lys Arg Leu Leu Met Asp Leu Asp Ile Asn Met	595
	75 80 85	
	cgc acg gtc gac tgt ttc tac act gtc acc ttc tac ggg gca cta ttc Arg Thr Val Asp Cys Phe Tyr Thr Val Thr Phe Tyr Gly Ala Leu Phe	643
	90 95 100	
10	aga gag gga gac gtg tgg atc tgc atg gag ctc atg gac aca tcc ttg Arg Glu Gly Asp Val Trp Ile Cys Met Glu Leu Met Asp Thr Ser Leu	691
	105 110 115	
15	gac aag ttc tac cgg aag gtg ctg gat aaa aac atg aca att cca gag Asp Lys Phe Tyr Arg Lys Val Leu Asp Lys Asn Met Thr Ile Pro Glu	739
	120 125 130	
	gac atc ctt ggg gag att gct gtg tct atc gtg cgg gcc ctg gag cat Asp Ile Leu Gly Glu Ile Ala Val Ser Ile Val Arg Ala Leu Glu His	787
	135 140 145 150	
20	ctg cac agc aag ctg tgc gtg atc cac aga gat gtg aag ccc tcc aat Leu His Ser Lys Leu Ser Val Ile His Arg Asp Val Lys Pro Ser Asn	835
	155 160 165	
25	gtc ctt atc aac aag gag ggc cat gtg aag atg tgt gac ttt ggc atc Val Leu Ile Asn Lys Glu Gly His Val Lys Met Cys Asp Phe Gly Ile	883
	170 175 180	
	agt ggc tac ttg gtg gac tct gtg gcc aag acg atg gat gcc ggc tgc Ser Gly Tyr Leu Val Asp Ser Val Ala Lys Thr Met Asp Ala Gly Cys	931
	185 190 195	
30	aag ccc tac atg gcc cct gag agg atc aac cca gag ctg aac cag aag Lys Pro Tyr Met Ala Pro Glu Arg Ile Asn Pro Glu Leu Asn Gln Lys	979
	200 205 210	
35	ggc tac aat gtc aag tcc gac gtc tgg agc ctg ggc atc acc atg att Gly Tyr Asn Val Lys Ser Asp Val Trp Ser Leu Gly Ile Thr Met Ile	1027
	215 220 225 230	
	gag atg gcc atc ctg cgg ttc cct tac gag tcc tgg ggg acc ccg ttc Glu Met Ala Ile Leu Arg Phe Pro Tyr Glu Ser Trp Gly Thr Pro Phe	1075
	235 240 245	
40	cag cag ctg aag cag gtg gtg gag gag ccg tcc ccc cag ctc cca gcc Gln Gln Leu Lys Gln Val Val Glu Glu Pro Ser Pro Gln Leu Pro Ala	1123
	250 255 260	
45	gac cgt ttc tcc ccc gag ttt gtg gac ttc act gct cag tgc ctg agg Asp Arg Phe Ser Pro Glu Phe Val Asp Phe Thr Ala Gln Cys Leu Arg	1171
	265 270 275	
	aag aac ccc gca gag cgt atg agc tac ctg gag ctg atg gag cac ccc Lys Asn Pro Ala Glu Arg Met Ser Tyr Leu Glu Leu Met Glu His Pro	1219
	280 285 290	
50	ttc ttc acc ttg cac aaa acc aag aag acg gac att gct gcc ttc gtg Phe Phe Thr Leu His Lys Thr Lys Lys Thr Asp Ile Ala Ala Phe Val	1267
	295 300 305 310	
55	aag aag atc ctg gga gaa gac tca tag gggctgggcc tcggacccca Lys Lys Ile Leu Gly Glu Asp Ser	1314
	315	

EP 1 201 765 A2

ctccggccct ccagagcccc acagccccat ctgcgggggc agtgcctcacc cacaccataa 1374
5 gctactgccca tcctggccca gggcatctgg gaggaaccga gggggctgct cccacctggc 1434
tctgtggcga gccatttgtc ccaagtgccca aagaagcaga ccattggggc tcccagccag 1494
gcccttgctg gccccaccag tgcctctccc tgtgtctcct aggaccgctc tccagctgct 1554
10 gagatcctgg actgaggggg cctggatgcc cctgtggat gctgctgccc ctgcacagca 1614
ggctgccagt gcctgggtgg atgggccacc gccttgccca gcctggatgc catccaagtt 1674
gtatatTTTT ttaatctctc gactgaatgg actttgcaca ctttggccca ggggtggccac 1734
15 acctctatcc cggttttggg gcggggtaca caagagggga tgagttgtgt gaatacccca 1794
agactcccat gaggagatg ccattgagccg cccaaggcct tccctggca ctggcaaaca 1854
gggcctctgc ggagcacact ggctcaccca gtctgcccgc ccacggttat cggtgtcatt 1914
20 cacctttcgt gtttttttta atttatcttc tgttgatttt ttcttttgct ttatgggttt 1974
ggcttggttt ttctgcatgg tttggagctg atcgcttctc cccaccccc tagggg 2030

<210> 2
25 <211> 318
<212> PRT
<213> Homo sapiens

<400> 2
30 Met Ser Lys Pro Pro Ala Pro Asn Pro Thr Pro Pro Arg Asn Leu Asp
1 5 10 15
Ser Arg Thr Phe Ile Thr Ile Gly Asp Arg Asn Phe Glu Val Glu Ala
20 25 30
Asp Asp Leu Val Thr Ile Ser Glu Leu Gly Arg Gly Ala Tyr Gly Val
35 40 45
Val Glu Lys Val Arg His Ala Gln Ser Gly Thr Ile Met Ala Val Lys
50 55 60
Arg Ile Arg Ala Thr Val Asn Ser Gln Glu Gln Lys Arg Leu Leu Met
65 70 75 80
Asp Leu Asp Ile Asn Met Arg Thr Val Asp Cys Phe Tyr Thr Val Thr
85 90 95
Phe Tyr Gly Ala Leu Phe Arg Glu Gly Asp Val Trp Ile Cys Met Glu
100 105 110
40 Leu Met Asp Thr Ser Leu Asp Lys Phe Tyr Arg Lys Val Leu Asp Lys
115 120 125
Asn Met Thr Ile Pro Glu Asp Ile Leu Gly Glu Ile Ala Val Ser Ile
130 135 140
45 Val Arg Ala Leu Glu His Leu His Ser Lys Leu Ser Val Ile His Arg
145 150 155 160
Asp Val Lys Pro Ser Asn Val Leu Ile Asn Lys Glu Gly His Val Lys
165 170 175
Met Cys Asp Phe Gly Ile Ser Gly Tyr Leu Val Asp Ser Val Ala Lys
180 185 190
50 Thr Met Asp Ala Gly Cys Lys Pro Tyr Met Ala Pro Glu Arg Ile Asn
195 200 205
Pro Glu Leu Asn Gln Lys Gly Tyr Asn Val Lys Ser Asp Val Trp Ser
210 215 220
Leu Gly Ile Thr Met Ile Glu Met Ala Ile Leu Arg Phe Pro Tyr Glu
225 230 235 240
55 Ser Trp Gly Thr Pro Phe Gln Gln Leu Lys Gln Val Val Glu Glu Pro
245 250 255
Ser Pro Gln Leu Pro Ala Asp Arg Phe Ser Pro Glu Phe Val Asp Phe

EP 1 201 765 A2

260 265 270
 Thr Ala Gln Cys Leu Arg Lys Asn Pro Ala Glu Arg Met Ser Tyr Leu
 275 280 285
 Glu Leu Met Glu His Pro Phe Phe Thr Leu His Lys Thr Lys Lys Thr
 290 295 300
 Asp Ile Ala Ala Phe Val Lys Lys Ile Leu Gly Glu Asp Ser
 305 310 315

SEQUENCE LISTING

<110> Axxima Pharmaceuticals AG

<120> CELLULAR KINASES INVOLVED IN CYTOMEGALOVIRUS INFECTION
AND THEIR INHIBITION

<130> U 88666

<140>

<141>

<160> 2

<170> PatentIn Ver. 2.1

<210> 1

<211> 3745

<212> DNA

<213> Homo sapiens

<220>

<221> CDS

<222> (188)..(2248)

<400> 1

gaattcggca cgaggccatt gaatcccagt cctaacagaa gtactgcaa tctgtggcc 60

tcattctgaa caaaagggat tagagaagaa aaatctcttg atataaggct tgaaagcaag 120

ggcaggcaat cttggttggtg aatattttct gatttttcca gaaatcaagc agaagattga 180

gctgctg atg tca gtt aac tct gag aag tgc tcc tct tca gaa agg ccg 229
 Met Ser Val Asn Ser Glu Lys Ser Ser Ser Ser Glu Arg Pro
 1 5 10

gag cct caa cag aaa gct cct tta gtt cct cct cct cca ccg cca cca 277
 Glu Pro Gln Gln Lys Ala Pro Leu Val Pro Pro Pro Pro Pro Pro Pro
 15 20 25 30

cca cca cca ccg cca cct ttg cca gac ccc aca ccc ccg gag cca gag 325
 Pro Pro Pro Pro Pro Pro Leu Pro Asp Pro Thr Pro Pro Glu Pro Glu
 35 40 45

gag gag atc ctg gga tca gat gat gag gag caa gag gac cct gcg gac 373
 Glu Glu Ile Leu Gly Ser Asp Asp Glu Glu Gln Glu Asp Pro Ala Asp
 50 55 60

tac tgc aaa ggt gga tat cat cca gtg aaa att gga gac ctc ttc aat 421
 Tyr Cys Lys Gly Gly Tyr His Pro Val Lys Ile Gly Asp Leu Phe Asn
 65 70 75

ggc cgg tat cat gtt att aga aag ctt gga tgg ggg cac ttc tct act 469
 Gly Arg Tyr His Val Ile Arg Lys Leu Gly Trp Gly His Phe Ser Thr
 80 85 90

EP 1 201 765 A2

5	gtc tgg ctg tgc tgg gat atg cag ggg aaa aga ttt gtt gca atg aaa Val Trp Leu Cys Trp Asp Met Gln Gly Lys Arg Phe Val Ala Met Lys 95 100 105 110	517
	ggt gta aaa agt gcc cag cat tat acg gag aca gcc ttg gat gaa ata Val Val Lys Ser Ala Gln His Tyr Thr Glu Thr Ala Leu Asp Glu Ile 115 120 125	565
10	aaa ttg ctc aaa tgt gtt cga gaa agt gat ccc agt gac cca aac aaa Lys Leu Leu Lys Cys Val Arg Glu Ser Asp Pro Ser Asp Pro Asn Lys 130 135 140	613
15	gac atg gtg gtc cag ctc att gac gac ttc aag att tca ggc atg aat Asp Met Val Val Gln Leu Ile Asp Asp Phe Lys Ile Ser Gly Met Asn 145 150 155	661
	ggg ata cat gtc tgc atg gtc ttc gaa gta ctt ggc cac cat ctc ctc Gly Ile His Val Cys Met Val Phe Glu Val Leu Gly His His Leu Leu 160 165 170	709
20	aag tgg atc atc aaa tcc aac tat caa ggc ctc cca gta cgt tgt gtg Lys Trp Ile Ile Lys Ser Asn Tyr Gln Gly Leu Pro Val Arg Cys Val 175 180 185 190	757
25	aag agt atc att cga cag gtc ctt caa ggg tta gat tac tta cac agt Lys Ser Ile Ile Arg Gln Val Leu Gln Gly Leu Asp Tyr Leu His Ser 195 200 205	805
	aag tgc aag atc att cat act gac ata aag ccg gaa aat atc ttg atg Lys Cys Lys Ile Ile His Thr Asp Ile Lys Pro Glu Asn Ile Leu Met 210 215 220	853
30	tgt gtg gat gat gca tat gtg aga aga atg gca gct gag cct gag ttg Cys Val Asp Asp Ala Tyr Val Arg Arg Met Ala Ala Glu Pro Glu Trp 225 230 235	901
35	cag aaa gca ggt gct cct cct cct tca ggg tct gca gtg agt acg gct Gln Lys Ala Gly Ala Pro Pro Pro Ser Gly Ser Ala Val Ser Thr Ala 240 245 250	949
	cca cag cag aaa cct ata gga aaa ata tct aaa aac aaa aag aaa aaa Pro Gln Gln Lys Pro Ile Gly Lys Ile Ser Lys Asn Lys Lys Lys Lys 255 260 265 270	997
40	ctg aaa aag aaa cag aag agg cag gct gag tta ttg gag aag cgc ctg Leu Lys Lys Lys Gln Lys Arg Gln Ala Glu Leu Leu Glu Lys Arg Leu 275 280 285	1045
45	cag gag ata gaa gaa ttg gag cga gaa gct gaa agg aaa ata ata gaa Gln Glu Ile Glu Glu Leu Glu Arg Glu Ala Glu Arg Lys Ile Ile Glu 290 295 300	1093
	gaa aac atc acc tca gct gca cct tcc aat gac cag gat ggc gaa tac Glu Asn Ile Thr Ser Ala Ala Pro Ser Asn Asp Gln Asp Gly Glu Tyr 305 310 315	1141
50	tgc cca gag gtg aaa cta aaa aca aca gga tta gag gag gcg gct gag Cys Pro Glu Val Lys Leu Lys Thr Thr Gly Leu Glu Glu Ala Ala Glu 320 325 330	1189
55	gca gag act gca aag gac aat ggt gaa gct gag gac cag gaa gag aaa Ala Glu Thr Ala Lys Asp Asn Gly Glu Ala Glu Asp Gln Glu Glu Lys 335 340 345 350	1237

EP 1 201 765 A2

5	gaa gat gct gag aaa gaa aac att gaa aaa gat gaa gat gat gta gat Glu Asp Ala Glu Lys Glu Asn Ile Glu Lys Asp Glu Asp Asp Val Asp 355 360 365	1285
10	cag gaa ctt gcg aac ata gac cct acg tgg ata gaa tca cct aaa acc Gln Glu Leu Ala Asn Ile Asp Pro Thr Trp Ile Glu Ser Pro Lys Thr 370 375 380	1333
15	aat ggc cat att gag aat ggc cca ttc tca ctg gag cag caa ctg gac Asn Gly His Ile Glu Asn Gly Pro Phe Ser Leu Glu Gln Gln Leu Asp 385 390 395	1381
20	gat gaa gat gat gat gaa gaa gac tgc cca aat cct gag gaa tat aat Asp Glu Asp Asp Asp Glu Glu Asp Cys Pro Asn Pro Glu Glu Tyr Asn 400 405 410	1429
25	ctt gat gag cca aat gca gaa agt gat tac aca tat agc agc tcc tat Leu Asp Glu Pro Asn Ala Glu Ser Asp Tyr Thr Tyr Ser Ser Ser Tyr 415 420 425 430	1477
30	gaa caa ttc aat ggt gaa ttg cca aat gga cga cat aaa att ccc gag Glu Gln Phe Asn Glu Leu Pro Asn Gly Arg His Lys Ile Pro Glu 435 440 445	1525
35	tca cag ttc cca gag ttt tcc acc tgc ttg ttc tct gga tcc tta gaa Ser Gln Phe Pro Glu Phe Ser Thr Ser Leu Phe Ser Gly Ser Leu Glu 450 455 460	1573
40	cct gtg gcc tgc ggc tct gtg ctt tct gag gga tca cca ctt act gag Pro Val Ala Cys Gly Ser Val Leu Ser Glu Gly Ser Pro Leu Thr Glu 465 470 475	1621
45	caa gag gag agc agt cca tcc cat gac aga agc aga acg gtt tca gcc Gln Glu Glu Ser Ser Pro Ser His Asp Arg Ser Arg Thr Val Ser Ala 480 485 490	1669
50	tcc agt act ggg gat ttg cca aaa gca aaa acc cgg gca gct gac ttg Ser Ser Thr Gly Asp Leu Pro Lys Ala Lys Thr Arg Ala Ala Asp Leu 495 500 505 510	1717
55	ttg gtg aat ccc ctg gat ccg cgg aat cga gat aaa att aga gta aaa Leu Val Asn Pro Leu Asp Pro Arg Asn Arg Asp Lys Ile Arg Val Lys 515 520 525	1765
60	att gct gac ctg gga aat gct tgt tgg gtg cat aaa cac ttc acg gaa Ile Ala Asp Leu Gly Asn Ala Cys Trp Val His Lys His Phe Thr Glu 530 535 540	1813
65	gac atc cag acg cgt cag tac cgc tcc ata gag gtt tta ata gga gcg Asp Ile Gln Thr Arg Gln Tyr Arg Ser Ile Glu Val Leu Ile Gly Ala 545 550 555	1861
70	ggg tac agc acc cct gcg gac atc tgg agc acg gcg tgt atg gca ttt Gly Tyr Ser Thr Pro Ala Asp Ile Trp Ser Thr Ala Cys Met Ala Phe 560 565 570	1909
75	gag ctg gca acg gga gat tat ttg ttt gaa cca cat tct ggg gaa gac Glu Leu Ala Thr Gly Asp Tyr Leu Phe Glu Pro His Ser Gly Glu Asp 575 580 585 590	1957
80	tat tcc aga gac gaa gac cac ata gcc cac atc ata gag ctg cta ggc Tyr Ser Arg Asp Glu Asp His Ile Ala His Ile Ile Glu Leu Leu Gly 595 600 605	2005

EP 1 201 765 A2

5 agt att cca agg cac ttt gct cta tct gga aaa tat tct cgg gaa ttc 2053
 Ser Ile Pro Arg His Phe Ala Leu Ser Gly Lys Tyr Ser Arg Glu Phe
 610 615 620
 ttc aat cgc aga gga gaa ctg cga cac atc acc aag ctg aag ccc tgg 2101
 Phe Asn Arg Arg Gly Glu Leu Arg His Ile Thr Lys Leu Lys Pro Trp
 625 630 635
 10 agc ctc ttt gat gta ctt gtg gaa aag tat ggc tgg ccc cat gaa gat 2149
 Ser Leu Phe Asp Val Leu Val Glu Lys Tyr Gly Trp Pro His Glu Asp
 640 645 650
 gct gca cag ttt aca gat ttc ctg atc ccg atg tta gaa atg gtt cca 2197
 15 Ala Ala Gln Phe Thr Asp Phe Leu Ile Pro Met Leu Glu Met Val Pro
 655 660 665 670
 gaa aaa cga gcc tca gct ggc gaa tgt cgg cat cct tgg ttg aat tct 2245
 Glu Lys Arg Ala Ser Ala Gly Glu Cys Arg His Pro Trp Leu Asn Ser
 675 680 685
 20 tag caaattctac caatattgca ttctgagcta gcaaattgttc ccagtacatt 2298
 ggacctaaac ggtgactctc attctttaac aggattacaa gtgagctggc ttcactctca 2358
 25 gacctttatt ttgctttgag gtactgttgt ttgacatttt gctttttgtg cactgtgatc 2418
 ctggggaagg gtagtctttt gtcttcagct aagtagttta ctgaccattt tcttctggaa 2478
 acaataacat gtctctaagc attgtttctt gtgttgtgtg acattcaaat gtcatttttt 2538
 30 tgaatgaaaa atactttccc ctttgtgttt tggcagggtt tgtaactatt tatgaagaaa 2598
 tatttttagct gagtactata taatttaciaa tcttaagaaa ttatcaagtt ggaaccaaga 2658
 aatagcaagg aaatgtacaa ttttatcttc tggcaaaggg acatcattcc tgtattatag 2718
 35 tgtatgtaaa tgcaccctgt aaatgttact ttccattaaa tatgggaggg ggactcaaat 2778
 ttcagaaaag ctaccaagtc ttgagtgcct tgtagcctat gttgcatgta gcggacttta 2838
 actgctccaa ggagtgtgtc aaacttttca ttccataaca gtcttttcac attggatttt 2898
 40 aaacaaagtg gctctgggtt ataagatgtc attctctata tggcacttta aaggaagaaa 2958
 agatatgttt ctcatctcaa aatatgcatt ataatttagc agtccattt gtgattttgc 3018
 atatttttaa aagtactttt aaagaagagc aatttcctt taaaaatgtg atggctcagt 3078
 45 accatgtcat gttgctctct ctgggcgctg taagttaagc tctacataga ttaaattgga 3138
 gaaacgtgtt aattgtgtgg aatgaaaaaa tacatatatt tttggaaaag catgatcatg 3198
 cttgtctaga acacaaggta tggatatatac aatttgagc gcagtgggca gaatacttct 3258
 50 cacagctcaa agataacagt gatecacatt attccatagg tagctttacg tgtggctaca 3318
 acaaatttta ctagcttttt cattgtcttt ccatgaaacg aagttgagaa aatgattttc 3378
 cttttgcagg ttgcacacag ttttgtttat gcatttcctt aaaattaatt gtagactcca 3438
 55 ggatacaaac catagtaggc aatacaattt agaatgtaat atatagaggt atattagcct 3498

EP 1 201 765 A2

ctttagaagt cagtggattg aatgtctttt ttttttaaatt tttacattca ttaaggtgcc 3558
5 tCGTTTTTga ctttgtccat taacatttat ccatatgcct ttgcaataac tagattgtga 3618
aaagctaaca agtgttgtaa caataatcca ttgtttgagg tgcttgccagt tgtcttataaa 3678
attaaagtgt tttggttttt ttttttccag aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa 3738
10 ttctctgc 3745

<210> 2
<211> 686
<212> PRT
15 <213> Homo sapiens

<400> 2
Met Ser Val Asn Ser Glu Lys Ser Ser Ser Ser Glu Arg Pro Glu Pro
1 5 10 15
Gln Gln Lys Ala Pro Leu Val Pro Pro Pro Pro Pro Pro Pro Pro
20 20 25 30
Pro Pro Pro Pro Leu Pro Asp Pro Thr Pro Pro Glu Pro Glu Glu Glu
35 40 45
Ile Leu Gly Ser Asp Asp Glu Glu Gln Glu Asp Pro Ala Asp Tyr Cys
50 55 60
Lys Gly Gly Tyr His Pro Val Lys Ile Gly Asp Leu Phe Asn Gly Arg
25 65 70 75 80
Tyr His Val Ile Arg Lys Leu Gly Trp Gly His Phe Ser Thr Val Trp
85 90 95
Leu Cys Trp Asp Met Gln Gly Lys Arg Phe Val Ala Met Lys Val Val
100 105 110
Lys Ser Ala Gln His Tyr Thr Glu Thr Ala Leu Asp Glu Ile Lys Leu
30 115 120 125
Leu Lys Cys Val Arg Glu Ser Asp Pro Ser Asp Pro Asn Lys Asp Met
130 135 140
Val Val Gln Leu Ile Asp Asp Phe Lys Ile Ser Gly Met Asn Gly Ile
145 150 155 160
His Val Cys Met Val Phe Glu Val Leu Gly His His Leu Leu Lys Trp
35 165 170 175
Ile Ile Lys Ser Asn Tyr Gln Gly Leu Pro Val Arg Cys Val Lys Ser
180 185 190
Ile Ile Arg Gln Val Leu Gln Gly Leu Asp Tyr Leu His Ser Lys Cys
195 200 205
Lys Ile Ile His Thr Asp Ile Lys Pro Glu Asn Ile Leu Met Cys Val
40 210 215 220
Asp Asp Ala Tyr Val Arg Arg Met Ala Ala Glu Pro Glu Trp Gln Lys
225 230 235 240
Ala Gly Ala Pro Pro Pro Ser Gly Ser Ala Val Ser Thr Ala Pro Gln
245 250 255
Gln Lys Pro Ile Gly Lys Ile Ser Lys Asn Lys Lys Lys Lys Leu Lys
45 260 265 270
Lys Lys Gln Lys Arg Gln Ala Glu Leu Leu Glu Lys Arg Leu Gln Glu
275 280 285
Ile Glu Glu Leu Glu Arg Glu Ala Glu Arg Lys Ile Ile Glu Glu Asn
290 295 300
Ile Thr Ser Ala Ala Pro Ser Asn Asp Gln Asp Gly Glu Tyr Cys Pro
50 305 310 315 320
Glu Val Lys Leu Lys Thr Thr Gly Leu Glu Glu Ala Ala Glu Ala Glu
325 330 335
Thr Ala Lys Asp Asn Gly Glu Ala Glu Asp Gln Glu Glu Lys Glu Asp
340 345 350
Ala Glu Lys Glu Asn Ile Glu Lys Asp Glu Asp Asp Val Asp Gln Glu
55 355 360 365
Leu Ala Asn Ile Asp Pro Thr Trp Ile Glu Ser Pro Lys Thr Asn Gly

370 375 380
 5 His Ile Glu Asn Gly Pro Phe Ser Leu Glu Gln Gln Leu Asp Asp Glu
 385 390 395 400
 Asp Asp Asp Glu Glu Asp Cys Pro Asn Pro Glu Glu Tyr Asn Leu Asp
 405 410 415
 Glu Pro Asn Ala Glu Ser Asp Tyr Thr Tyr Ser Ser Ser Tyr Glu Gln
 420 425 430
 10 Phe Asn Gly Glu Leu Pro Asn Gly Arg His Lys Ile Pro Glu Ser Gln
 435 440 445
 Phe Pro Glu Phe Ser Thr Ser Leu Phe Ser Gly Ser Leu Glu Pro Val
 450 455 460
 Ala Cys Gly Ser Val Leu Ser Glu Gly Ser Pro Leu Thr Glu Gln Glu
 465 470 475 480
 15 Glu Ser Ser Pro Ser His Asp Arg Ser Arg Thr Val Ser Ala Ser Ser
 485 490 495
 Thr Gly Asp Leu Pro Lys Ala Lys Thr Arg Ala Ala Asp Leu Leu Val
 500 505 510
 Asn Pro Leu Asp Pro Arg Asn Arg Asp Lys Ile Arg Val Lys Ile Ala
 515 520 525
 20 Asp Leu Gly Asn Ala Cys Trp Val His Lys His Phe Thr Glu Asp Ile
 530 535 540
 Gln Thr Arg Gln Tyr Arg Ser Ile Glu Val Leu Ile Gly Ala Gly Tyr
 545 550 555 560
 Ser Thr Pro Ala Asp Ile Trp Ser Thr Ala Cys Met Ala Phe Glu Leu
 565 570 575
 25 Ala Thr Gly Asp Tyr Leu Phe Glu Pro His Ser Gly Glu Asp Tyr Ser
 580 585 590
 Arg Asp Glu Asp His Ile Ala His Ile Ile Glu Leu Leu Gly Ser Ile
 595 600 605
 30 Pro Arg His Phe Ala Leu Ser Gly Lys Tyr Ser Arg Glu Phe Phe Asn
 610 615 620
 Arg Arg Gly Glu Leu Arg His Ile Thr Lys Leu Lys Pro Trp Ser Leu
 625 630 635 640
 Phe Asp Val Leu Val Glu Lys Tyr Gly Trp Pro His Glu Asp Ala Ala
 645 650 655
 35 Gln Phe Thr Asp Phe Leu Ile Pro Met Leu Glu Met Val Pro Glu Lys
 660 665 670
 Arg Ala Ser Ala Gly Glu Cys Arg His Pro Trp Leu Asn Ser
 675 680 685
 40

Claims

1. Method for identifying compounds useful for treating and/or preventing Cytomegalovirus infection and/or associated diseases comprising:

- a) contacting a test compound with one or more cellular kinases selected from the group consisting of RICK, RIP, NIK, MKK3, and SRPK-2; and
- b) detecting a change in activity of said cellular kinase.

2. Method for detecting Cytomegalovirus infection and/or associated diseases in an individual comprising:

- a) providing a sample from said individual; and
- b) detecting activity, in said sample, of one or more cellular kinases selected from the group consisting of RICK, RIP, NIK, MKK3, and SRPK-2.

3. Method for detecting Cytomegalovirus infection and/or associated diseases in cells and/or cell lysates comprising:

- a) providing a sample from said cells; and
- b) detecting activity, in said sample, of one or more cellular kinases selected from the group consisting of RICK, RIP, NIK, MKK3, and SRPK-2.

4. A monoclonal or polyclonal antibody that binds to a cellular kinase selected from the group consisting of RICK, RIP, NIK, MKK3, and SRPK-2.
5. Method for preventing and/or treating Cytomegalovirus infection and/or associated diseases in an individual by administering a pharmaceutically effective amount of an inhibitor to said individual, wherein said inhibitor inhibits at least partially the activity of one or more cellular kinases selected from the group consisting of RICK, RIP, NIK, MKK3, and SRPK-2, or wherein said inhibitor inhibits at least partially the production of one or more cellular kinases selected from the group consisting of RICK, RIP, NIK, MKK3, and SRPK-2.
6. Method for regulating the production of Cytomegalovirus in an individual by administering an individual a pharmaceutically effective amount of an inhibitor wherein said inhibitor inhibits at least partially the activity of one or more cellular kinases selected from the group consisting of RICK, RIP, NIK, MKK3, and SRPK-2, or wherein said inhibitor at least partially inhibits the production of one or more cellular kinases selected from the group consisting of RICK, RIP, NIK, MKK3, and SRPK-2.
7. Method for regulating the production of Cytomegalovirus in cells by administering the cells a pharmaceutically effective amount of an inhibitor wherein said inhibitor inhibits at least partially the activity of one or more cellular kinases selected from the group consisting of RICK, RIP, NIK, MKK3, and SRPK-2, or wherein said inhibitor at least partially inhibits the production of one or more cellular kinases selected from the group consisting of RICK, RIP, NIK, MKK3, and SRPK-2 in the cells.
8. Method according to claim 5, 6, or 7 wherein the inhibitor is a monoclonal or polyclonal antibody which binds to a cellular kinase selected from the group consisting of RICK, RIP, NIK, MKK3, and SRPK-2.
9. Method for preventing and/or treating Cytomegalovirus infection and/or associated diseases in an individual by administering a pharmaceutically effective amount of an activator to said individual, wherein said activator activates at least partially the activity of one or more cellular kinases selected from the group consisting of RICK, RIP, NIK, MKK3, and SRPK-2, or wherein said activator activates or stimulates at least partially the production of one or more cellular kinases selected from the group consisting of RICK, RIP, NIK, MKK3, and SRPK-2.
10. Method for regulating the production of Cytomegalovirus in an individual by administering an individual a pharmaceutically effective amount of an activator wherein said activator activates at least partially the activity of one or more cellular kinases selected from the group consisting of RICK, RIP, NIK, MKK3, and SRPK-2, or wherein said activator at least partially activates or stimulates the production of one or more cellular kinases selected from the group consisting of RICK, RIP, NIK, MKK3, and SRPK-2.
11. Method for regulating the production of Cytomegalovirus in cells by administering the cells a pharmaceutically effective amount of an activator wherein said activator activates at least partially the activity of one or more cellular kinases selected from the group consisting of RICK, RIP, NIK, MKK3, and SRPK-2, or wherein said activator at least partially activates or stimulates the production of one or more cellular kinases selected from the group consisting of RICK, RIP, NIK, MKK3, and SRPK-2 in the cells.
12. Oligonucleotide that binds to the DNA or RNA encoding a cellular kinase selected from the group consisting of RICK, RIP, NIK, MKK3, and SRPK-2.
13. Method for regulating the expression of at least one cellular kinase selected from the group consisting of RICK, RIP, NIK, MKK3, and SRPK-2 in an individual comprising the step of administering the individual a pharmaceutically effective amount of an inhibitor wherein said inhibitor inhibits at least partially the transcription of DNA or the translation of RNA encoding one of said cellular kinases.
14. Method for regulating the expression of at least one cellular kinase selected from the group consisting of RICK, RIP, NIK, MKK3, and SRPK-2 in cells comprising the step of administering the cells a pharmaceutically effective amount of an inhibitor wherein said inhibitor inhibits at least partially the transcription of DNA or the translation of RNA encoding one of said cellular kinases.

15. Method according to claim 5, 6, 7, 13, or 14 wherein the inhibitor is a oligonucleotide which binds to the DNA and/or RNA encoding a cellular kinase selected from the group consisting of RICK, RIP, NIK, MKK3, and SRPK-2.

16. Method for regulating the expression of at least one cellular kinase selected from the group consisting of RICK, RIP, NIK, MKK3, and SRPK-2 in an individual comprising the step of administering the individual a pharmaceutically effective amount of an activator wherein said activator activates at least partially the transcription of DNA or the translation of RNA encoding one of said cellular kinases.

17. Method for regulating the expression of at least one cellular kinase selected from the group consisting of RICK, RIP, NIK, MKK3, and SRPK-2 in cells comprising the step of administering the cells a pharmaceutically effective amount of an activator wherein said activator activates at least partially the transcription of DNA or the translation of RNA encoding one of said cellular kinases.

18. A solid support useful for detecting Cytomegalovirus infection of an individual comprising one or more immobilized oligonucleotides, wherein said oligonucleotide(s) is (are) capable of detecting activity of one or more cellular kinases selected from the group consisting of: RICK, RIP, NIK, MKK3, and SRPK-2.

19. A solid support useful for detecting Cytomegalovirus infection of cells comprising one or more immobilized oligonucleotides, wherein said oligonucleotide(s) is (are) capable of detecting activity of one or more cellular kinases selected from the group consisting of RICK, RIP, NIK, MKK3, and SRPK-2.

20. A solid support useful for screening compounds useful for treating and/or preventing Cytomegalovirus infection comprising one or more immobilized oligonucleotides, wherein said oligonucleotide(s) encode one or more cellular kinases selected from the group consisting of RICK, RIP, NIK, MKK3, and SRPK-2.

21. A solid support useful for screening compounds useful for treating and/or preventing Cytomegalovirus infection comprising one or more immobilized cellular kinases selected from the group consisting of RICK, RIP, NIK, MKK3, and SRPK-2.

22. Composition useful to treat an individual afflicted with Cytomegalovirus and/or associated diseases comprising one or more inhibitors capable of inhibiting activity of one or more cellular kinases selected from the group consisting of RICK, RIP, NIK, MKK3, and SRPK-2 or capable of decreasing the expression of at least one cellular kinase selected from the group consisting of RICK, RIP, NIK, MKK3, and SRPK-2.

23. Composition useful to treat an individual afflicted with Cytomegalovirus and/or associated diseases comprising one or more activators capable of increasing activity of one or more cellular kinases selected from the group consisting of RICK, RIP, NIK, MKK3, and SRPK-2 or capable of increasing the expression of at least one cellular kinase selected from the group consisting of RICK, RIP, NIK, MKK3, and SRPK-2.

24. Composition useful to treat an individual afflicted with Cytomegalovirus comprising at least one compound selected from the group consisting of

6-(2,6-Dichlorophenyl)-8-methyl-2-(3-morpholin-4-yl-propylamino)-8H-pyrido[2,3-d]pyrimidin-7-one;
8-methyl-6-phenyl-2-(pyridin-4-yl-amino)-8H-pyrido[2,3-d]pyrimidin-7-one;
6-(2,6-Dichlorophenyl)-8-methyl-2-[3-(4-methylpiperazin-1-yl)-propylamino]-8H-pyrido[2,3-d]pyrimidin-7-one;
(3-Bromophenyl)-(6,7-dimethoxyquinazolin-4-yl)-amine;
(3-Bromophenyl)-(6,7-diethoxyquinazolin-4-yl)-amine;
2-(3,4-Dihydroxyphenyl)-3,5,7-trihydroxychromen-4-one;
5-Chloro-3-(1H-pyrrol-2-ylmethylene)-1,3-dihydroindol-2-one;
4-Quinolin-4-ylmethylene-4H-isoquinoline-1,3-dione

and/or pharmaceutically acceptable salts of these compounds.

25. Composition according to any one of claims 17 - 19 further comprising pharmaceutically acceptable carriers, excipient, and/or diluents.

26. Use of the compounds selected from the group comprising:

EP 1 201 765 A2

6-(2,6-Dichlorophenyl)-8-methyl-2-(3-morpholin-4-yl-propylamino)-8H-pyrido[2,3-d]pyrimidin-7-one;
8-methyl-6-phenyl-2-(pyridin-4-yl-amino)-8H-pyrido[2,3-d]pyrimidin-7-one;
6-(2,6-Dichlorophenyl)-8-methyl-2-[3-(4-methylpiperazin-1-yl)-propylamino]-8H-pyrido[2,3-d]pyrimidin-7-one;

(3-Bromophenyl)-(6,7-dimethoxyquinazolin-4-yl)-amine;
(3-Bromophenyl)-(6,7-diethoxyquinazolin-4-yl)-amine and

pharmaceutically acceptable salts of these compounds as an inhibitor of the cellular kinase RICK.

27. Use of the compounds selected from the group comprising:

2-(3,4-Dihydroxyphenyl)-3,5,7-trihydroxychromen-4-one;
5-Chloro-3-(1 H-pyrrol-2-ylmethylene)-1,3-dihydroindol-2-one;
4-Quinolin-4-ylmethylene-4H-isoquinoline-1,3-dione; and

pharmaceutically acceptable salts of these compounds as an inhibitor of the cellular kinase RIP.

28. Use of a compound according to claim 26 or 27 for the manufacture of a pharmaceutical composition for prophylaxis and/or treatment of Cytomegalovirus infection and/or diseases associated therewith.

Figures

Fig. 1




Fig. 2

